TW201424762A - 包含鋅-胺基酸複合物的口腔用凝膠 - Google Patents
包含鋅-胺基酸複合物的口腔用凝膠 Download PDFInfo
- Publication number
- TW201424762A TW201424762A TW102143368A TW102143368A TW201424762A TW 201424762 A TW201424762 A TW 201424762A TW 102143368 A TW102143368 A TW 102143368A TW 102143368 A TW102143368 A TW 102143368A TW 201424762 A TW201424762 A TW 201424762A
- Authority
- TW
- Taiwan
- Prior art keywords
- zinc
- amino acid
- acid
- dentifrice
- composition
- Prior art date
Links
- 229940041672 oral gel Drugs 0.000 title description 14
- 239000011701 zinc Substances 0.000 claims abstract description 116
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 98
- -1 zinc amide halide Chemical class 0.000 claims abstract description 69
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000000551 dentifrice Substances 0.000 claims abstract description 39
- 239000011787 zinc oxide Substances 0.000 claims abstract description 30
- 238000010790 dilution Methods 0.000 claims abstract description 28
- 239000012895 dilution Substances 0.000 claims abstract description 28
- 210000003296 saliva Anatomy 0.000 claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims description 75
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 69
- 239000002253 acid Substances 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 37
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 28
- 238000001556 precipitation Methods 0.000 claims description 23
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 18
- 239000004475 Arginine Substances 0.000 claims description 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- 239000004472 Lysine Substances 0.000 claims description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 16
- 229910019142 PO4 Inorganic materials 0.000 claims description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 16
- 210000003298 dental enamel Anatomy 0.000 claims description 16
- 150000004820 halides Chemical class 0.000 claims description 15
- 239000002243 precursor Substances 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000003906 humectant Substances 0.000 claims description 11
- 239000003082 abrasive agent Substances 0.000 claims description 10
- 201000002170 dentin sensitivity Diseases 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 239000002562 thickening agent Substances 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 208000007565 gingivitis Diseases 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- 206010044038 Tooth erosion Diseases 0.000 claims description 6
- HFFROHHGHGDACO-JEDNCBNOSA-N [Zn].NCCCC[C@H](N)C(Cl)=O Chemical group [Zn].NCCCC[C@H](N)C(Cl)=O HFFROHHGHGDACO-JEDNCBNOSA-N 0.000 claims description 6
- 229920006318 anionic polymer Polymers 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 208000036595 non-bacterial tooth erosion Diseases 0.000 claims description 6
- 239000007787 solid Chemical class 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 238000005530 etching Methods 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 230000010065 bacterial adhesion Effects 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- UJNPHNKJSKIVTE-SCGRZTRASA-L zinc;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CCCNC(N)=N.[O-]C(=O)[C@@H](N)CCCNC(N)=N UJNPHNKJSKIVTE-SCGRZTRASA-L 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000008376 breath freshener Substances 0.000 claims 1
- 230000007797 corrosion Effects 0.000 claims 1
- 238000005260 corrosion Methods 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 159000000001 potassium salts Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 description 202
- 229940024606 amino acid Drugs 0.000 description 101
- 235000001014 amino acid Nutrition 0.000 description 92
- 239000000499 gel Substances 0.000 description 35
- 238000009472 formulation Methods 0.000 description 34
- 210000004268 dentin Anatomy 0.000 description 28
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 24
- 239000002324 mouth wash Substances 0.000 description 22
- 229940051866 mouthwash Drugs 0.000 description 22
- 239000000460 chlorine Substances 0.000 description 21
- 229960003646 lysine Drugs 0.000 description 19
- 239000000606 toothpaste Substances 0.000 description 18
- 235000018977 lysine Nutrition 0.000 description 17
- 210000005239 tubule Anatomy 0.000 description 17
- 229960003121 arginine Drugs 0.000 description 16
- 235000009697 arginine Nutrition 0.000 description 15
- 235000021317 phosphate Nutrition 0.000 description 15
- 229940034610 toothpaste Drugs 0.000 description 15
- 229940091249 fluoride supplement Drugs 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 239000002245 particle Substances 0.000 description 12
- 239000011775 sodium fluoride Substances 0.000 description 12
- 235000013024 sodium fluoride Nutrition 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 230000008021 deposition Effects 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 230000036541 health Effects 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000003945 anionic surfactant Substances 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 208000002925 dental caries Diseases 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 235000011180 diphosphates Nutrition 0.000 description 7
- 238000005189 flocculation Methods 0.000 description 7
- 230000016615 flocculation Effects 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 150000003751 zinc Chemical class 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- KFVPJMZRRXCXAO-UHFFFAOYSA-N [He].[O] Chemical compound [He].[O] KFVPJMZRRXCXAO-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical group O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 229940083542 sodium Drugs 0.000 description 6
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 6
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 235000019832 sodium triphosphate Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 208000006558 Dental Calculus Diseases 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 4
- 229940043256 calcium pyrophosphate Drugs 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000004088 foaming agent Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000001307 helium Substances 0.000 description 4
- 229910052734 helium Inorganic materials 0.000 description 4
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 244000060011 Cocos nucifera Species 0.000 description 3
- 235000013162 Cocos nucifera Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 3
- 229920000388 Polyphosphate Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000002272 anti-calculus Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 3
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 239000000571 coke Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000009616 inductively coupled plasma Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000005498 polishing Methods 0.000 description 3
- 239000001205 polyphosphate Substances 0.000 description 3
- 235000011176 polyphosphates Nutrition 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960000414 sodium fluoride Drugs 0.000 description 3
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 3
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 3
- 229960002799 stannous fluoride Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000036347 tooth sensitivity Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 229960003500 triclosan Drugs 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- DDKJKQVNNATMAD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;zinc Chemical compound [Zn].NCCCC[C@H](N)C(O)=O DDKJKQVNNATMAD-JEDNCBNOSA-N 0.000 description 2
- YFVBASFBIJFBAI-UHFFFAOYSA-M 1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=CC=C1 YFVBASFBIJFBAI-UHFFFAOYSA-M 0.000 description 2
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 2
- SKWCZPYWFRTSDD-UHFFFAOYSA-N 2,3-bis(azaniumyl)propanoate;chloride Chemical compound Cl.NCC(N)C(O)=O SKWCZPYWFRTSDD-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-O carboxymethyl-[3-(dodecanoylamino)propyl]-dimethylazanium Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)=O MRUAUOIMASANKQ-UHFFFAOYSA-O 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- QSFOWAYMMZCQNF-UHFFFAOYSA-N delmopinol Chemical compound CCCC(CCC)CCCC1COCCN1CCO QSFOWAYMMZCQNF-UHFFFAOYSA-N 0.000 description 2
- 229960003854 delmopinol Drugs 0.000 description 2
- 238000005115 demineralization Methods 0.000 description 2
- 230000002328 demineralizing effect Effects 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium phosphate dihydrate Substances O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 2
- 201000005581 enamel erosion Diseases 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 150000004673 fluoride salts Chemical class 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000012433 hydrogen halide Substances 0.000 description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 239000001683 mentha spicata herb oil Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical group COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 2
- 229960001245 olaflur Drugs 0.000 description 2
- MMCOUVMKNAHQOY-UHFFFAOYSA-L oxido carbonate Chemical compound [O-]OC([O-])=O MMCOUVMKNAHQOY-UHFFFAOYSA-L 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940043230 sarcosine Drugs 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- 235000019721 spearmint oil Nutrition 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011746 zinc citrate Substances 0.000 description 2
- 235000006076 zinc citrate Nutrition 0.000 description 2
- 229940068475 zinc citrate Drugs 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FEIQOMCWGDNMHM-KBXRYBNXSA-N (2e,4e)-5-phenylpenta-2,4-dienoic acid Chemical compound OC(=O)\C=C\C=C\C1=CC=CC=C1 FEIQOMCWGDNMHM-KBXRYBNXSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- AAQVSSUWJKCMTP-XRIGFGBMSA-N (2s)-2,6-diaminohexanoic acid;zinc;hydrochloride Chemical group Cl.[Zn].NCCCC[C@H](N)C(O)=O AAQVSSUWJKCMTP-XRIGFGBMSA-N 0.000 description 1
- ZINGPVGWKVTAAC-IAROGAJJSA-N (2z,4e)-2-chlorohexa-2,4-dienoic acid Chemical compound C\C=C\C=C(/Cl)C(O)=O ZINGPVGWKVTAAC-IAROGAJJSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- JLPAMKUIIFHLBH-UHFFFAOYSA-N 1,2-dihydroxypropane-1-sulfonic acid Chemical compound CC(O)C(O)S(O)(=O)=O JLPAMKUIIFHLBH-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- OZCMOJQQLBXBKI-UHFFFAOYSA-N 1-ethenoxy-2-methylpropane Chemical compound CC(C)COC=C OZCMOJQQLBXBKI-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- RWMSXNCJNSILON-UHFFFAOYSA-N 2-[4-(2-propylpentyl)piperidin-1-yl]ethanol Chemical compound CCCC(CCC)CC1CCN(CCO)CC1 RWMSXNCJNSILON-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical group Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- SZTBMYHIYNGYIA-UHFFFAOYSA-N 2-chloroacrylic acid Chemical compound OC(=O)C(Cl)=C SZTBMYHIYNGYIA-UHFFFAOYSA-N 0.000 description 1
- FQHUWSPRTMWLFA-UHFFFAOYSA-N 2-cyclohexylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1CCCCC1 FQHUWSPRTMWLFA-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- UOWIFEANNONTKY-UHFFFAOYSA-N 2-hydroxy-5-octanoyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CCCCCCCC(=O)C1=CC=C(O)C(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 UOWIFEANNONTKY-UHFFFAOYSA-N 0.000 description 1
- VZMJQFZZUNSSNA-UHFFFAOYSA-N 2-methylpropane-1-sulfonic acid prop-2-en-1-amine Chemical compound NCC=C.CC(C)CS(O)(=O)=O VZMJQFZZUNSSNA-UHFFFAOYSA-N 0.000 description 1
- ONPJWQSDZCGSQM-UHFFFAOYSA-N 2-phenylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1=CC=CC=C1 ONPJWQSDZCGSQM-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CYUZOYPRAQASLN-UHFFFAOYSA-N 3-prop-2-enoyloxypropanoic acid Chemical compound OC(=O)CCOC(=O)C=C CYUZOYPRAQASLN-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- IAWHLWBVNHODET-UHFFFAOYSA-N 4-ethyl-1-tetradecylpyridin-1-ium Chemical compound CCCCCCCCCCCCCC[N+]1=CC=C(CC)C=C1 IAWHLWBVNHODET-UHFFFAOYSA-N 0.000 description 1
- ANAAMBRRWOGKGU-UHFFFAOYSA-M 4-ethyl-1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=C(CC)C=C1 ANAAMBRRWOGKGU-UHFFFAOYSA-M 0.000 description 1
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 1
- 239000004261 Ascorbyl stearate Substances 0.000 description 1
- LITUBCVUXPBCGA-WMZHIEFXSA-N Ascorbyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O LITUBCVUXPBCGA-WMZHIEFXSA-N 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- YNHSACUDMWXKIW-UHFFFAOYSA-N C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[NH4+].[F].[NH4+].[NH4+] Chemical compound C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[NH4+].[F].[NH4+].[NH4+] YNHSACUDMWXKIW-UHFFFAOYSA-N 0.000 description 1
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical class [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CQVPPLWYIDMWDA-UHFFFAOYSA-N OS(=O)(=O)c1ccccc1.CCCCCCCCCCCC[Na] Chemical compound OS(=O)(=O)c1ccccc1.CCCCCCCCCCCC[Na] CQVPPLWYIDMWDA-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical class [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 description 1
- ROLJWXCAVGNMAK-UHFFFAOYSA-N [Ce]=O Chemical compound [Ce]=O ROLJWXCAVGNMAK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002053 acidogenic effect Effects 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- 229940039407 aniline Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002882 anti-plaque Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000019276 ascorbyl stearate Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- PVEOYINWKBTPIZ-UHFFFAOYSA-N but-3-enoic acid Chemical compound OC(=O)CC=C PVEOYINWKBTPIZ-UHFFFAOYSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- IISIZTZBVOYMAH-UHFFFAOYSA-K calcium;sodium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Na+].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O IISIZTZBVOYMAH-UHFFFAOYSA-K 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LDCRTTXIJACKKU-ARJAWSKDSA-N dimethyl maleate Chemical compound COC(=O)\C=C/C(=O)OC LDCRTTXIJACKKU-ARJAWSKDSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfonate Chemical compound [O-]S(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical class ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- KPRZOPQOBJRYSW-UHFFFAOYSA-N o-hydroxybenzylamine Natural products NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 1
- 229950002404 octapinol Drugs 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-K peroxyphosphate Chemical compound [O-]OP([O-])([O-])=O MPNNOLHYOHFJKL-UHFFFAOYSA-K 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 229940116254 phosphonic acid Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 1
- 239000010672 sassafras oil Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940045990 sodium laureth-2 sulfate Drugs 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940045872 sodium percarbonate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- GUQPDKHHVFLXHS-UHFFFAOYSA-M sodium;2-(2-dodecoxyethoxy)ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOS([O-])(=O)=O GUQPDKHHVFLXHS-UHFFFAOYSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- HFQQZARZPUDIFP-UHFFFAOYSA-M sodium;2-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O HFQQZARZPUDIFP-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- LVLJBRFCYXMKCE-UHFFFAOYSA-N sulfo dodecanoate Chemical compound CCCCCCCCCCCC(=O)OS(O)(=O)=O LVLJBRFCYXMKCE-UHFFFAOYSA-N 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- XROWMBWRMNHXMF-UHFFFAOYSA-J titanium tetrafluoride Chemical compound [F-].[F-].[F-].[F-].[Ti+4] XROWMBWRMNHXMF-UHFFFAOYSA-J 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- SYMVZGYNJDKIPL-UHFFFAOYSA-H tricalcium;oxido phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]OP([O-])([O-])=O.[O-]OP([O-])([O-])=O SYMVZGYNJDKIPL-UHFFFAOYSA-H 0.000 description 1
- VBIJGJLWKWLWHQ-UHFFFAOYSA-K trisodium;oxido phosphate Chemical compound [Na+].[Na+].[Na+].[O-]OP([O-])([O-])=O VBIJGJLWKWLWHQ-UHFFFAOYSA-K 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- VSJRDSLPNMGNFG-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O VSJRDSLPNMGNFG-UHFFFAOYSA-H 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229940006486 zinc cation Drugs 0.000 description 1
- 229940085658 zinc citrate trihydrate Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/58—Metal complex; Coordination compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
本文係揭示包括鋅胺酸鹵化物之潔牙劑,其因使用經水及/或唾液稀釋而提供一沉澱氧化鋅。亦提供製造和使用此等潔牙劑之方法。
Description
本文係揭示包括鋅胺酸鹵化物之潔牙劑,其因使用經水及/或唾液稀釋而提供一沉澱氧化鋅。亦提供製造和使用此等潔牙劑之方法。
牙齒蛀蝕係涉及去礦化作用以及由於非細菌性來源之酸侵襲所致之牙齒結構的傷害。蛀蝕最初係在琺瑯質中發現,若未受遏止可能進行至下方的牙本質。牙齒蛀蝕可能經由酸性食物和飲料、暴露於經氯消毒的泳池水及胃酸逆流所造成或更加劇。牙齒琺瑯質為一負電荷表面,其本質上傾向吸引正電荷離子例如氫和鈣離子,同時阻抗負電荷離子例如氟化物離子。依照週圍唾液之相對pH,牙齒琺瑯質會失去或得到正電荷離子例如鈣離子。一般而言,唾液具有介於7.2至7.4之pH。當pH降低及氫離子濃度變得相當高時,氫離子將會置換琺瑯質中的鈣離子,形成磷酸氫(磷酸),其會傷害琺瑯質並造成多孔性、類海綿之粗糙表面。若唾液長時間仍為酸性,則再礦化作用可能不會發生且牙齒將持續流失礦物質,造成牙齒弱化及最後結構流失。
牙齒敏感為回應牙本質表面因暴露的牙本質受到熱(熱或冷)滲透、熱接觸組合、滲透和接觸刺激之物理性刺激的急性、局部牙齒疼痛。牙本質之暴露,一般係由於牙齦萎縮或琺瑯質流失所致,常常導致過敏。
牙本質小管開通至表面與牙本質敏感具有高度相關性。牙本質小管係由牙髓通往牙骨質。當牙根的表面牙骨質受侵襲,牙本質小管開始暴露於外界環境。暴露的牙本質提供液流傳送到牙髓神經之通路,此傳送係由於溫度、壓力和離子梯度之變化所引起。
重金屬離子例如鋅對於酸侵襲具有阻抗性。在電位序次上鋅排在氫之上,所以當鋅進入溶液,金屬鋅在酸性溶液中將會與游離的氫氣反應,形成二-陽離子Zn2+。在牙菌斑和齲齒研究中鋅已顯示具有抗細菌性質。
可溶性鋅鹽例如檸檬酸鋅,已用於潔牙劑組成物中,參見,例如美國專利第6,121,315號,但有數個缺點。在溶液中鋅離子給予一種不愉悅、澀的口感,所以提供有效量以及具有可接受感官感知性質的鋅之組成物,難以達成。最後,鋅離子會與陰離子界面活性劑例如月桂基硫酸鈉反應,因而妨礙起泡性和清潔性。氧化鋅和不溶性的鋅鹽很難將鋅遞送至牙齒,因為其不溶性。
在先前技術揭示供治療牙齒敏感、牙齒蛀蝕和琺瑯質蛀蝕之各種口腔組成物的同時,對於提供改善此等治療之性能的另外組成物和方法仍有需要。
目前已發現鋅離子可與胺基酸形成可溶性複合物。包括鋅和胺基酸及視需要陰離子及/或氧之複合物,形成一可溶性陽離子基團,其反之可與鹵化物或其他陰離子形成一鹽類。當置於調配物中時,此複合物提供琺瑯質一有效濃度的鋅離子,藉此保護免於蛀蝕、降低細菌定植及生物膜生成,並促進牙齒閃亮。再者,因使用,此調配物提供可阻塞牙本質小
管之沉澱物,藉此降低牙齒敏感性。相較於含不溶性鋅鹽之調配物,在提供有效遞送鋅之同時,此等包括鋅-胺基酸複合物之調配物不具有與使用可溶性鋅鹽之習用鋅-基底的口腔保健產品有關之拙劣的味道和口感、拙劣的氟化物遞送和拙劣的起泡性和清潔性。
在一特別的實施例中,此鋅-胺基酸複合物為一鋅-離胺酸-HCl複合物,例如稱為ZLC之新穎的複合物,其可由氧化鋅和離胺酸鹽酸鹽之混合物形成。ZLC具有化學結構[Zn(C6H14N2O2)2Cl]+ Cl-,並可以陽離子性陽離子([Zn(C6H14N2O2)2Cl]+)和氯陰離子之溶液存在,或可為固體鹽,例如晶體,視需要單或二-水合物形式。
本發明因此係提供包括鋅-胺基酸複合物,例如鋅-離胺酸-氯化物複合物,例如ZLC之口腔保健組成物,例如漱口水、口腔凝膠或潔牙劑組成物。此等組成物可視需要進一步包括一氟化物來源或另外的磷酸鹽來源。此等組成物可調配於適合的口腔保健調配物,例如習用的潔牙劑、口腔凝膠或漱口水基底中,例如係包括一或多種研磨劑、界面活性劑、起泡劑、維生素、聚合物、酵素、保濕劑、增稠劑、抗微生物劑、防腐劑、調味劑及/或著色劑。
在一特別的實施例中,本發明係提供口腔凝膠組成物,例如包括一鋅-胺基酸複合物,例如鋅-離胺酸-氯化物複合物,例如ZLC,其在調配時為澄清的,但當以水稀釋時則提供氧化鋅沉澱。
本發明進一步係提供使用本發明組成物用以降低和抑制琺瑯質酸蝕、清潔牙齒、降低細菌產生的生物膜和牙菌斑、降低牙齦炎、抑制牙齒齲蝕和形成蛀洞以及降低牙本質過敏之方法,其包括將本發明之組成物施用於牙齒。
本發明進一步係提供製造本發明組成物之方法,其包括將鋅離子來源(例如ZnO)、胺基酸(例如鹼性胺基酸,例如精胺酸或離胺酸),及視需要鹵化物來源組合,例如將氧化鋅和離胺酸鹽酸鹽於水性溶液中組合,例如以1:1至1:3之Zn:胺基酸的莫耳比率,例如1:2,以及1:1至1:3之Zn:存在的鹵化物,例如1:2;視需要將離子複合物分離由此形成一固體;及與口腔凝膠基底混合。
由下文所提供的詳細說明,本發明進一步的適用領域將變得顯而易見。應了解,詳細說明和特定實例,當指出本發明之較佳實施例時,係希望僅供說明之目的而不希望限制本發明之範圍。
下列較佳實施例之說明本質上僅為示例性而不希望在任何方面限制本發明、其應用或用途。
本發明因此在第一實施例中係提供一包括鋅與胺基酸複合之口腔凝膠組成物(組成物1);例如,
1.1.組成物1,其中胺基酸係選自游離或口腔可接受酸加成鹽形式,例如鹽酸鹽形式之離胺酸、甘胺酸和精胺酸。
1.2.組成物1或1.1,其中該胺基酸為鹼性胺基酸,例如游離或口腔可接受鹽形式之精胺酸或離胺酸。
1.3.任何前述之組成物,進一步係包括與鋅和胺基酸結合之離子性鹵化物。
1.4.任何前述之組成物,其中Zn:胺基酸之莫耳比率係從3:1至1:5,例如約1:2,而Zn:存在的鹵化合物之莫耳比率係從3:1至1:3,例如約1:2。
1.5.任何前述之組成物,其中該鋅-胺基酸複合物,整體或部分係在施用組成物後於原位形成。
1.6.任何前述之組成物,其中該鋅-胺基酸複合物,整體或部分係在組成物調配後於原位形成。
1.7.任何前述之組成物,其中該胺基酸為離胺酸。
1.8.任何前述之組成物,其中鋅係以組成物之重量計0.05至10%之量存在,視需要以組成物之重量計至少0.1,至少0.2,至少0.3,至少0.4,至少0.5,至少1,至少2,至少3,或至少4至高10%,例如約1-3%,例如約2-2.7%重量比。
1.9.任何前述之組成物,其中胺基酸係以組成物之重量計0.05至30%之量存在,視需要至少0.1,至少0.2,至少0.3,至少0.4,至少0.5,至少1,至少2,至少3,至少4,至少5,至少10,至少15,至少20至高30%重量比,例如約1-10%重量比。
1.10.任何前述之組成物,其中鋅與胺基酸之莫耳比率為2:1至1:4,視需要1:1至1:4,1:2至1:4,1:3至1:4,2:1至1:3,2:1至1:2,或2:1至1:1,例如約1:2或1:3。
1.11.任何前述之組成物,係包括與鋅和胺基酸離子性結合之鹵化物,其中該鹵化物係由氟、氯及其混合物組成之群中選出。
1.12.任何前述之組成物,其中該鋅胺基酸複合物為鋅離胺酸氯化物複合物(例如,(ZnLys2 Cl)+Cl-或(ZnLys3)2+Cl2)或鋅精胺酸氯化物複合物。
1.13.任何前述之組成物,中該鋅胺基酸複合物為鋅離胺酸氯化物複合物,例如ZLC,例如具有化學結構[Zn(C6H14N2O2)2Cl]+ Cl-之鋅離胺酸氯化物複合物,其為陽離子性陽離子(例如[Zn(C6H14N2O2)2Cl]+)和氯化物陰
離子之溶液或固體鹽形式,例如晶體形式,視需要單或二-水合物形式。
1.14.任何前述之組成物,為一澄清凝膠形式,其當稀釋時提供氧化鋅沉澱。
1.15.任何前述之組成物,為一潔牙劑形式,例如其中鋅-胺基酸複合物係以一有效量,例如0.5-4%重量比之鋅,例如約1-3%重量比之鋅,存在於潔牙劑基底中。
1.16.任何前述之組成物,為一潔牙劑形式,其中該潔牙劑基底係包括一研磨劑,例如一有效量之矽氧研磨劑,例如10-30%,例如約20%。
1.17.任何前述之組成物,其中該鋅-胺基酸複合物係以一有效量存在,例如0.1-3%重量比之鋅量,例如約0.2-1%重量比之鋅。
1.18.任何前述之組成物,進一步係包括一有效量之氟化物離子來源,例如提供500至3000ppm氟化物。
1.19.任何前述之組成物,進一步係包括一有效量之氟化物,例如其中氟化物為一選自氟化亞錫、氟化鈉、氟化鉀、單氟磷酸鈉、氟矽酸鈉、氟矽酸銨、氟化胺(N'-十八基三伸甲基二胺-N,N,N'-叁(2-乙醇)-二氫氟化物)、氟化銨、氟化鈦、六氟硫酸鹽之鹽及其組合物。
1.20.任何前述之組成物,係包括一有效量之一或多種鹼性磷酸鹽,例如鈉、鉀或鈣鹽,例如選自鹼性磷酸氫鹽和鹼性焦磷酸鹽,例如選自磷酸氫二鈉、磷酸氫二鉀、磷酸二鈣二水合物、焦磷酸鈣、焦磷酸四鈉、焦磷酸四鉀、三聚磷酸鈉之鹼性磷酸鹽及任何二或多種此等之混合物,例如以組成物的重量計1-20%,例如2-8%,例如約5%之量。
1.21.任何前述之組成物,係包括緩衝劑,例如磷酸鈉緩衝劑(例如磷酸二氫鈉和磷酸二鈉)。
1.22.任何前述之組成物,係包括保濕劑,例如選自甘油、山梨醇、丙二醇、聚乙二醇、木糖醇及其混合物,例如包括至少20%,例如20-40%,例如25-35%甘油。
1.23.任何前述之組成物,係包括一或多種界面活性劑,例如選自陰離子、陽離子、兩性離子和非離子及其混合物,例如係包括一陰離子界面活性劑,例如選自月桂基硫酸鈉、月桂基醚硫酸鈉及其混合物之界面活性劑,例如從約0.3%至約4.5%重量比之量,例如1-2%的月桂基硫酸鈉(SLS);及/或兩性離子界面活性劑,例如甜菜鹼界面活性劑,例如椰油醯胺丙基甜菜鹼,例如從約0.1%至約4.5%重量比之量,例如0.5-2%椰油醯胺丙基甜菜鹼。
1.24.任何前述之組成物,進一步係包括黏度調變量之一或多種的多糖膠,例如三仙膠或鹿角菜膠、矽氧增稠劑及其組合物。
1.25.任何前述之組成物,係包括膠條或膠片。
1.26.任何前述之組成物,進一步係包括調味劑、香精及/或調色劑。
1.27.任何前述之組成物,係包括一有效量之一或多種抗細菌劑,例如包括由下列選出之抗細菌劑:鹵素化二苯基醚(例如三氯沙)、香草萃取物和精油(例如迷迭香萃取物、茶萃取物、木蘭萃取物、百里醇、薄荷醇、桉油醇、香葉醇、香芹酚、檸檬醛、扁柏酚、兒茶酚、水楊酸甲酯、表沒食子兒茶素沒食子酸酯(epigallocatechin gallate)、表沒食子兒茶素(epigallocatechin)、沒食子酸、美斯瓦克(miswak)萃取物、沙棘萃取物)、雙胍類抗菌劑(例如氯己定(chlorhexidine)、阿來西定(alexidine)或奧替尼啶(octenidine))、四級銨化合物(例如十六烷基氯化吡錠(CPC)、苯紮氯銨(benzalkonium chloride)、十四烷基氯化吡錠(TPC)、N-十四烷基-4-乙基氯化吡錠(TDEPC))、酚系殺菌劑、海克替啶(hexetidine)、奧替尼
啶(octenidine)、血根鹼(sanguinarine)、聚維酮碘(povidone iodine)、地莫匹醇(delmopinol)、5-正辛醯-3'-三氟甲基苯基水楊醯胺(salifluor)、金屬離子(如鋅鹽,如檸檬酸鋅,亞錫鹽、銅鹽、鐵鹽)、血根鹼、蜂膠和氧化劑(如過氧化氫、緩衝的過氧硼酸鈉或過氧碳酸鹽)、酞酸及其鹽類、單酞酸(monoperthalicacid)及其鹽類和酯類、抗壞血酸硬脂酸酯、油醯肌胺酸、硫酸烷基酯、磺基琥珀酸二辛酯、水楊醯苯胺、溴化度米芬(domiphen bromide)、地莫匹醇、辛哌醇(octapinol)和其他哌啶基衍生物、nicin製備物、亞氯酸鹽類;以及任何前述之混合物;例如包括三氯沙或十六烷基氯化吡錠。
1.28.任何前述之組成物,係包括抗細菌上有效量之三氯沙,例如0.1-0.5%,例如約0.3%。
1.29.任何前述之組成物,進一步係包括,例如由下列組成之群中選出之增白劑:過氧化物、金屬亞氯酸鹽、過硼酸鹽、過碳酸鹽、過氧酸、次氯酸鹽及其組合物。
1.30.任何前述之組成物,進一步係包括過氧化氫或過氧化氫來源,例如尿素過氧化物或過氧化物鹽或複合物(例如過氧磷酸鹽、過氧碳酸鹽、過硼酸鹽、過氧矽酸鹽或過硫酸鹽;例如過氧磷酸鈣、過硼酸鈉、過氧碳酸鈉、過氧磷酸鈉和過硫酸鉀);
1.31.任何前述之組成物,進一步係包括干擾或防止細菌黏附之試劑,例如尼泊金丙酯(solbrol)或幾丁聚醣。
1.32.任何前述之組成物,進一步係包括選自(i)鈣-玻璃複合物,例如磷矽酸鈉鈣,及(ii)鈣-蛋白複合物,例如酪蛋白磷酸肽-非晶磷酸鈣之鈣和磷酸來源
1.33.任何前述之組成物,進一步係包括可溶性鈣鹽,例如選自硫酸鈣、氯化鈣、硝酸鈣、乙酸鈣、乳酸鈣及其組合物。
1.34.任何前述之組成物,進一步係包括有效降低牙本質敏感量之生理上或口腔上可接受的鉀鹽,例如硝酸鉀或氯化鉀。
1.35.任何前述之組成物,進一步係包括陰離子聚合物,例如合成的陰離子聚合性聚羧酸鹽,例如其中該陰離子聚合物係選自馬來酸酐或酸與另外的可聚合乙烯化不飽和單體之1:4至4:1的共聚物,例如其中該陰離子聚合物為具有約30,000至約1,000,000,例如約300,000至約800,000平均分子量(M.W.)之甲基乙烯基醚/馬來酸酐(PVM/MA)共聚物,例如其中該陰離子聚合物,以組成物重量計為約1-5%,例如約2%。
1.36.任何前述之組成物,進一步係包括一呼吸清新劑、香精或調味劑。
1.37.任何前述之組成物,其中組成物的pH為約中性,例如從pH 6至pH 8,例如約pH 7。
1.38.任何前述之組成物,為口腔凝膠之形式,其中該胺基酸為離胺酸,且鋅和離胺酸係形成具有化學結構[Zn(C6H14N2O2)2Cl]+ Cl-之鋅-離胺酸-氯化物複合物,為提供0.1-2%,例如約0.5%鋅重量比之量,且進一步係包括45-65%,例如約50-60%之量之保濕劑,例如山梨醇、丙二醇及其混合物,例如0.1-2%之量的增稠劑,例如纖維素衍生物,例如選自羧甲基纖維素(CMC)、三甲基纖維素(TMC)及其混合物,甜味劑及/或調味劑和水,例如口腔凝膠係包括
1.39.任何前述之組成物,係用於降低和抑制琺瑯質酸蝕、清潔牙齒、降低細菌產生的生物膜和牙菌斑、降低牙齦炎、抑制牙齒齲蝕和形成蛀洞以及降低牙本質過敏。
本發明進一步係提供降低和抑制琺瑯質酸蝕、清潔牙齒、降低細菌產生的生物膜和牙菌斑、降低牙齦炎、抑制牙齒齲蝕和形成蛀洞以及降低牙本質過敏之方法,其係包括將一有效量之本發明化合物,例如任何組成物1及以下組成物施予牙齒,及然後視需要用足以從組成物引發氧化鋅沉澱之水或水溶液沖洗。
本發明進一步係提供製造包括鋅胺基酸複合物之口腔保健組成物,例如任何組成物1及以下組成物的方法,其係包括將鋅離子來源與游離或鹽形式之胺基酸,於水性媒劑中組合(例如將氧化鋅與離胺酸鹽酸鹽組合),視需要分離此複合物由此形成的固體鹽形式,並將此複合物與口腔保健基底,例如潔牙劑或漱口水基底組合。
例如,在各種實施例中,本發明係提供(i)降低牙齒過敏,(ii)降低牙菌斑堆積,(iii)降低或抑制去礦化作用並促進牙齒再礦化,(iv)抑制口腔中微生物生物膜形成,(v)降低或抑制牙齦炎,(vi)促進口中傷口或割傷之癒合,(vii)降低產酸菌的量,(viii)增加非致齲性及/或非牙菌斑形成細菌之相對量,(ix)降低或抑制齲齒形成,(x)降低、修復或抑制琺瑯質之齲前病灶,例如藉由定量光學螢光(QLF)或電子齲蝕監測器(ECM)偵測,(xi)治療、舒緩或降低口乾,(xii)清潔牙齒和口腔,(xiii)降低蛀蝕,(xiv)牙齒增白;(xv)
降低酒石形成,及/或(xvi)促進全身健康,包括心血管健康,例如藉由降低經由口腔組織之全身性感染的潛在性之方法,其係包括將如上述之任何組成物1及以下的組成物施用於有此需要之個人的口腔,例如每天一或多次。本發明進一步係提供組成物1及以下的組成物供用於任何這些方法中。
本發明進一步係提供鋅和胺基酸用於製造包括鋅胺基酸複合物之口腔保健組成物的用途。
本發明進一步係提供鋅胺基酸複合物,例如鋅胺基酸鹵化物,例如鋅-離胺酸-氯化物複合物用於降低和抑制琺瑯質酸蝕、清潔牙齒、降低細菌產生的生物膜和牙菌斑、降低牙齦炎、抑制牙齒齲蝕和形成蛀洞及/或降低牙本質過敏之用途。
不受限於理論,咸信鋅胺基酸鹵化物之形成係經由形成鋅鹵化物然後環繞中央鋅與胺基酸殘基配位來進行。使用ZnO與離胺酸鹽酸鹽於水中反應為例,鋅可與離胺酸及/或離胺酸HCl反應形成澄清的Zn-離胺酸-氯化物複合物(ZnLys3Cl2)溶液,其中Zn++係位於與分別來自二個離胺酸羧酸和胺基基團之二個氧和二個氮原子在赤道面配位的八面體中心。鋅亦經由其氮和羧酸氧在金屬幾何形狀的頂點與第三離胺酸配位。
在另外的實施例中,鋅陽離子係與二個胺基酸殘基和二個氯化物殘基複合。例如,當此胺基酸為離胺酸時,此複合物具有化學式[Zn(C6H14N2O2)2Cl]+Cl-。在此複合物中,Zn陽離子係藉由二個離胺酸配體與二個來自NH2基團的N原子和來自羧酸基團的O原子於赤道面配位。其出現了一頂端位置被Cl-原子佔據之扭曲的四方錐幾合形狀。此新穎的結構產生一正陽離子基團,一Cl-基團係與其結合而形成離子鹽。
其他鋅和胺基酸之複合物為可能的,且精確的形式係部份依照前驅化合物之莫耳比率而定,例如若鹵化物受限,則可能形成無鹵化物
之複合物,例如具有金字塔幾何形狀之ZnOLys2,其中赤道平面係與上述化合物相同(Zn係與來自不同離胺酸的二個氧和二個氮結合),其中金字塔頂端係被O原子所佔據。
複合物之混合物及/或另外複雜的結構,例如包括以鋅結構為基礎之多個鋅離子,為可能的並涵蓋在本發明之範圍內。當複合物為固體形式時,其可能形成晶體,例如水合形式。
不論該(等)複合物之精確結構,然而鋅與胺基酸之相互作用在約中性pH將不溶性的氧化鋅或鋅鹽轉變成高可溶性複合物。然而隨著水中稀釋度增加,複合物解離,此鋅離子轉變為不溶性氧化鋅。此動態為意料之外的-典型地離子組成物在較高的稀釋度下可溶性會變得更高,而非更低-且此項幫助鋅沉澱物因施用,在唾液之存在下及沖洗下而沉積在牙齒上。此沉澱阻塞了牙本質小管,藉此降低過敏,且亦提供鋅給琺瑯質,其降低了酸蝕、生物膜和牙菌斑形成。
應了解,在前述流程中可使用其他胺基酸取代離胺酸。亦應了解,雖然鋅、胺基酸和視需要的鹵化物可能主要為前驅物形式或離子複合物形式,其在某些程度上為平衡的,所以實際上為複合物之物質的比例,相較於前驅物形式的比例,依照調配物之精確的條件、物質濃度、pH、有或無水存在、有或無其他帶電分子存在等等可能不同。
活性物可以任何的口腔保健調配物形式來遞送,例如牙膏、凝膠、漱口水、牙粉、乳膏、條片、膠或任何其他本項技術中已知者。
若活性物係以漱口水的形式來遞送,需要此項利益之個人以儲存溶液和唾液之天然儲存溶液的稀釋液沖洗將會引發鋅之沉澱。另外,該個人亦可將儲存溶液與適量的水性稀釋劑(例如,就鋅-離胺酸樣本約1份儲存溶液和8份水),並以此混合物沖洗。
在另外的實施例中,係製備此混合物並立即轉置於牙托盤,例如該等用於裝盛潔白凝膠者,該個人可戴著此托盤一段有效的時間。便可處理與此混合物接觸之牙齒。就以牙托盤來使用而言,此混合物可為低黏度液體或凝膠之形式。
在另外的實施例中,儲存溶液或儲存溶液與水之混合物,係以凝膠調配物施用於牙齒,例如其中該凝膠可留在牙齒上歷經一段有效處理之延長的時間。
在另外的實施例中,活性物係以牙膏來提供。因刷洗,活性物被唾液和水稀釋,導致沉澱和沉積物和阻塞粒子形成。
調配物之沉澱速率可藉由調整複合物在儲存溶液中的濃度及改變儲存液與水的比率來調節。當希望快速處理時,較稀的調配物產生較快的沉澱且因此為較佳。
本發明口腔保健組成物之利益眾多。藉由提供鋅離子和在口腔中可釋放鋅離子之含鋅化合物,本發明口腔保健組成物提供了抗微生物、抗牙菌斑、抗牙齦炎、抗臭、抗齲蝕和抗牙結石利益。阻塞粒子和表面沉積為含鋅化合物(特別是ZnO),以及可將鋅離子釋放至口腔並提供各種上述已知利益之其他鋅衍生物。另外的利益包括(但不限於)抗黏附、抗牙周炎及抗骨質流失,以及促進傷口癒合。
第二項利益為鋅離子經由氧化和水解在牙齒表面形成抗蛀蝕沉積物之抗蛀蝕性質。表面沉積物,以及阻塞粒子可與酸反應並中和酸,因此保護牙齒表面免於酸之侵蝕效應。就此,處理時引起越多表面沉積/阻塞,則處理越有效,且因此鋅-精胺酸和鋅-離胺酸為較佳。同時請注意,當表面沉積和阻塞粒子中和酸時,可能釋放有利的鋅離子和胺基酸(下文),提供抗-蛀蝕以外的口腔保健利益。
第三項利益為由阻塞所產生之抗過敏利益。阻塞牙本質小管使敏感緩解。
第四項利益為與胺基酸有關的利益。阻塞粒子和表面沉積含有對應的胺基酸,例如精胺酸和離胺酸。這些胺基酸提供多種利益。例如,鹼性胺基酸使牙菌斑的pH較高並可提供抗齲利益。此外,亦預期精胺酸可增進精胺酸分解細菌之活性,產生更健康的牙菌斑。精胺酸已知亦促進傷口癒合和膠原蛋白完整。
組成物可包括鋅胺基酸鹵化物及/或其前驅物。前驅物,其可在原位與水反應形成鋅胺基酸鹵化物,包括(i)鋅和胺基酸氫鹵化物,或(ii)氯化鋅和胺基酸,或(iii)鋅離子來源、胺基酸及鹵酸,或(iv)(i)、(ii)及/或(iii)之組合。在一實施例中,鋅胺基酸鹵化物可於室溫藉由將前驅物於溶液,例如水中混合來製備。原位形成使調配容易。可使用前驅物取代必須先形成胺基酸鹵化物。在另外的實施例中,能讓前驅物形成鋅胺基酸鹵化物之水係來自唾液及/或施用後與組成物接觸之沖洗水。
鋅胺基酸鹵化物為水溶性複合物,其係由鋅之鹵酸加成鹽(例如氯化鋅)和胺基酸所形成,或由胺基酸之鹵酸加成鹽(例如離胺酸鹽酸鹽)和鋅離子來源所形成,及/或由所有三種鹵酸、胺基酸和鋅離子來源之組合所形成。
胺基酸之實例包括(但不限於)常見天然胺基酸,例如離胺酸、精胺酸、組胺酸、甘胺酸、絲胺酸、蘇胺酸、天門冬醯胺酸、麩醯胺酸、半胱胺酸、硒半胱胺酸、脯胺酸、丙胺酸、纈胺酸、異白胺酸、白胺酸、甲硫胺酸、苯丙胺酸、酪胺酸、色胺酸、天門冬胺酸及麩胺酸。在某些實施例中,此胺基酸為天然或酸性胺基酸,例如甘胺酸。
由下列實例可看出,當複合物係由鹼性胺基酸所形成時,因以水稀釋而來自複合物的沉澱為最顯著。因此,當藉由稀釋來沉澱為所欲時,鹼性胺基酸可能較佳。在某些實施例中,因此,該胺基酸為鹼性胺基酸。「鹼性胺基酸」係指天然生成的鹼性胺基酸,例如精胺酸、離胺酸和組胺酸,以及在分子中具有羧基基團和胺基基團之任何鹼性胺基酸,其為水溶性並提供帶有約7或更高之pH的水溶液。因此,鹼性胺基酸包括(但不限於)精胺酸、離胺酸、瓜胺酸、鳥胺酸、肌胺酸、組胺酸、二胺基丁酸、二胺基丙酸、其鹽類或其組合物。在特定的實施例中,此鹼性胺基酸為離胺酸。在其他的實施例中,此胺基酸為精胺酸。
鹵化物可為氯、溴或碘,最典型地為氯。胺基酸和鹵酸之酸加成鹽(例如HCl、HBr或HI)有時在本處係指胺基酸氫鹵化物。因此一胺酸氫鹵化物之實例為離胺酸鹽酸鹽。另一為甘胺酸鹽酸鹽。
用於與胺基酸鹵化物或胺基酸視需要加上鹵酸組合之鋅離子來源在此情況下可為,例如氧化鋅或氯化鋅。
在特定的實施例中,組成物中鋅胺基酸鹵化物的量,以組成物的重量計為0.05至10%。在特定實施例中,前驅物,例如鋅和胺基酸氫鹵化物存在量,係以當組合成鋅胺基酸鹵化物時,該鋅胺基酸鹵化物應以組成物的重量計0.05至10%之量存在。在任一這些實施例中,鋅胺基酸鹵化物之量可就所欲的目的,例如潔牙或漱口水而不同。在其他的實施例中,鋅胺基酸鹵化物之量,以組成物的重量計為至少0.1,至少0.2,至少0.3,至少0.4,至少0.5,至少1,至少2,至少3,或至少4至高10%。在其他的實施例中,鋅胺基酸鹵化物之量,以組成物的重量計係低於9,低於8,低於7,低於6,低於5,低於4,低於3,低於2,低於1,低於0.5至0.05%。在其他的實施例中,此量,以組成物的重量計為0.05至5%,0.05至
4%,0.05至3%,0.05至2%,0.1至5%,0.1至4%,0.1至3%,0.1至2%,0.5至5%,0.5至4%,0.5至3%或0.5至2%。
在特定實施例中,鋅係以組成物的重量計0.05至10%之量存在。在其他的實施例中,鋅之量以組成物的重量計為至少0.1,至少0.2,至少0.3,至少0.4,至少0.5,至少1,至少2,至少3,或至少4至高10%。在其他的實施例中,鋅之量,以組成物的重量計係低於9,低於8,低於7,低於6,低於5,低於4,低於3,低於2,低於1,低於0.5至0.05%。在其他的實施例中,該等量,以組成物的重量計為0.05至5%,0.05至4%,0.05至3%,0.05至2%,0.1至5%,0.1至4%,0.1至3%,0.1至2%,0.5至5%,0.5至4%,0.5至3%或0.5至2%。
在特定實施例中,胺基酸氫鹵化物係以0.05至30%重量比之量存在。在其他實施例中,此量為至少0.1,至少0.2,至少0.3,至少0.4,至少0.5,至少1,至少2,至少3,至少4,至少5,至少10,至少15,至少20至高30%重量比。在其他的實施例中,此量以組成物的重量計係低於30,低於25,低於20,低於15,低於10,低於5,低於4,低於3,低於2,或低於1低至0.05%。
當前驅物質存在時,其較佳地係以大約產生所欲的鋅胺基酸鹵化物所需之莫耳比率存在,雖然在特定的調配物中過量的某種物質可能為所希望,例如平衡pH對抗其他調配物組成份,提供另外的抗細菌鋅,或提供胺基酸緩衝劑。然而,較佳地係限制鹵化物之量,因為限制鹵化物的量會些許助長鋅和胺基酸間的相互作用。
在某些實施例中,組成物中的總鋅量,以組成物的重量計為0.05至8%。在其他的實施例中,總鋅量,以組成物的重量計為至少0.1,至少0.2,至少0.3,至少0.4,至少0.5或至少1至高8%。在其他的實施例
中,組成物中的總鋅量,以組成物的重量計係低於5,低於4,低於3,低於2,或低於1至0.05%。
在特定實施例中,鋅與胺基酸之莫耳比率為至少2:1。在其他的實施例中,莫耳比率為至少1:1,至少1:2,至少1:3,至少1:4,2:1至1:4,1:1至1:4,1:2至1:4,1:3至1:4,2:1至1:3,2:1至1:2,2:1至1:1,或1:3。1:4以上,預計鋅將可完全溶解。
在特定實施例中,此組成物為無水的。無水為具有低於5%重量比的水,視需要低於4,低於3,低於2,低於1,低於0.5,低於0.1低至0%重量比的水。
當以無水組成物提供時,前驅物,例如TBZC和胺基酸氫鹵化物,明顯地將不會反應形成鋅胺基酸鹵化物。當與足量的水(其可為唾液及/或施用組成物後用於沖洗口部之水)接觸時,前驅物然後將會反應形成鋅胺基酸鹵化物,然後因進一步的稀釋,將提供牙齒含鋅的沉澱。
載劑係代表組成物中鋅胺基酸鹵化物複合物或其前驅物以外的所有其他物質。載劑的量為加上鋅胺基酸鹵化物(包括任何前驅物)重量,達到100%之量。
活性劑:包括或除了鋅-胺基酸-鹵化物複合物外,本發明之組成物可包括各種對於保護和增進琺瑯質以及牙齒結構之強度和完整性及/或降低細菌和相關牙齒蛀蝕及/或牙齦疾病有效之試劑。用於文中之活性成份的有效濃度將依所用的特定試劑和遞送系統而定。請了解,例如牙膏典型地於使用時會以水稀釋,漱口水典型地則否。因此,牙膏中活性劑的有效濃度一般將比漱口水所要求高5-15x。濃度亦將依確切的鹽或所選的聚合物而定。例如,當活性劑係以鹽形式提供時,相對離子將會影響鹽的重量,所以若相對離子越重將需要更高重量比的鹽,以提供最終產物中相同的活
性離子濃度。精胺酸,若存在時,可以從例如約0.1至約20重量%(以游離鹼的重量表示)之量存在,例如就消費者牙膏約1至約10重量%,或就專業或處方治療產品約7至約20重量%。氟化物,若存在時,可以例如約25至約25,000ppm之量存在,例如就消費者牙膏為750至2,000ppm,或就專業或處方治療產品為2,000至25,000ppm。抗細菌劑之量同樣地可不同,用於牙膏中的量比用於漱口水中的量多例如約5至約15倍。例如三氯沙牙膏可含有0.3%重量比的三氯沙。
氟化物離子來源:口腔保健組成物可進一步包括一或多種氟化物離子來源,例如可溶性氟化物鹽類。可使用廣泛各種產生氟化物離子之物質作為本組合物中之可溶性氟化物。適合的產生氟化物離子之物質的實例係參見Briner等人之美國專利第3,535,421號、Parran,Jr.等人之美國專利第4,885,155號及Widder等人之美國專利第3,678,154號。代表性的氟化物離子來源包括(但不限於)氟化亞錫、氟化鈉、氟化鉀、單氟磷酸鈉、氟矽酸鈉、氟矽酸銨、氟化胺、氟化銨及其組合物。在特定的實施例中,氟化物離子來源包括氟化亞錫、氟化鈉、單氟磷酸鈉以及其混合物。在特定的實施例中,本發明之口腔保健組成物亦含有足以供應約25ppm至5,000ppm氟化物離子之量的氟化物離子或氟提供成份,一般至少約500ppm,例如約500至約2000ppm,例如約1000至約1600ppm,例如1450ppm。適當的氟化物之量將依特定的施用而定。供一般消費者使用的牙膏典型地可具有約1000至約1500ppm,而兒童牙膏可具有較少一些。供專業用途之潔牙劑或塗料可具有約5,000或甚至約25,000ppm的氟化物。氟化物離子來源可以組合物之重量計約0.01%至約10%之量加至組成物中,在一實施例中約0.03至約5%,而在另外的實施例中約0.1%至約1%。提供適量氟化物離子之氟化物鹽類的重量明顯地將以鹽中相對離子的重量為基準而變。
胺基酸:在某些實施例中,本發明之組成物係包括一胺基酸。在特定的實施例中,胺基酸可為鹼性胺基酸。「鹼性胺基酸」係指天然生成的鹼性胺基酸,例如精胺酸、離胺酸和組胺酸,以及在分子中具有羧基基團和胺基基團之任何鹼性胺基酸,其為水溶性並提供帶有約7或更高之pH的水溶液。因此,鹼性胺基酸包括(但不限於)精胺酸、離胺酸、瓜胺酸、鳥胺酸、肌胺酸、組胺酸、二胺基丁酸、二胺基丙酸、其鹽類或其組合物。在特定的實施例中,此鹼性胺基酸係選自精胺酸、瓜胺酸和鳥胺酸。在特定的實施例中,此鹼性胺基酸為精胺酸,例如1-精胺酸或其鹽。
在各種實施例中,胺基酸係以總組成物重量之約0.5重量%至約20重量%,總組成物重量之約0.5重量%至約10重量%之量存在,例如就潔牙劑的情況約總組成物重量之1.5重量%,約3.75重量%,約5重量%或約7.5重量%,或例如就漱口水的情況約0.5-2重量%,例如約1%。
研磨劑:本發明之組成物,例如組成物1以及以下組成物,係包括矽氧研磨劑,並可包括另外的研磨劑,例如磷酸鈣研磨劑,例如磷酸三鈣(Ca3(PO4)2)、羥磷灰石(Ca10(PO4)6(OH)2)或磷酸氫鈣二水合物(CaHPO4‧2H2O,文中有時亦稱DiCal)或焦磷酸鈣;碳酸鈣研磨劑;或例如偏磷酸鈉、偏磷酸鉀、矽酸鋁、煅燒氧化鋁、膨潤土或其他矽質物質或其組合物之研磨劑。
可用於本文之其他矽氧研磨拋光物質以及其他研磨劑,一般係具有範圍介於約0.1至約30微米,介於約5至約15微米之平均粒子大小。矽氧研磨劑可來自沉澱矽氧或矽氧凝膠,例如,Pader等人之美國專利第3,538,230號及Digiulio之美國專利第3,862,307號中所描述的矽氧乾凝膠(silica xerogel)。特定的矽氧乾凝膠有W.R.Grace & Co.,Davison Chemical Division所販售的商品名Syloid®。沉澱矽氧物質包括J.M.Huber公司所販
售的商品名Zeodent®,包括名稱Zeodent 115和119之矽氧。這些矽氧研磨劑係描述於Wason之美國專利第4,340,583號中。在特定的實施例中,可用於施行本發明之口腔保健組成物之有用的研磨物質包括具有低於約100毫升/100克矽氧及約45毫升/100克至約70毫升/100克矽氧範圍內吸油值之矽氧凝膠及沉澱非晶矽氧。吸油值係使用ASTA Rub-Out Method D281所測量。在特定的實施例中,矽氧為具有約3微米至約12微米及約5至約10微米之平均粒子大小的膠體粒子。特別可用於本發明施行中之低吸油矽氧研磨劑為Davison Chemical Division of W.R.Grace & Co.,Baltimore,Md.21203所販售的商品名Sylodent XWA®。Sylodent 650 XWA®,一種由膠狀矽氧粒子所組成的矽氧水凝膠,具有約29%重量比之水含量,平均直徑約7至約10微米,及低於約70cc/100g矽氧之吸油性,為可用於本發明施行中之低吸油矽氧研磨劑的實例。
起泡劑:本發明之口腔保健組成物亦可包括當刷洗口腔時增加所產生的泡沫量之試劑。增加泡沫量試劑之說明性實例包括(但不限於)聚氧乙烯及特定的聚合物,包括(但不限於)藻酸鹽聚合物。聚氧乙烯可增加泡沫的量及由口腔保健載劑組份所產生之泡沫的厚度。聚氧乙烯一般亦稱為聚乙二醇("PEG")或聚環氧乙烷。適用於本發明之聚氧乙烯係具有約200,000至約7,000,000之分子量。在一實施例中,分子量係為約600,000至約2,000,000,及在另一實施例中為約800,000至約1,000,000。Polyox®為由聯合碳化物公司(Union Carbide)所生產的高分子量聚氧乙烯之商品名稱。聚氧乙烯,以本發明口腔保健組成物之口腔保健載劑組份的重量計,可以約1%至約90%之量存在,在一實施例中為約5%至約50%,而在另一實施例中為約10%至約20%。若存在時,口腔保健組成物中起泡劑的量(亦即單一
劑量)為約0.01至約0.9%重量比,約0.05至約0.5%重量比,及在另外的實施例中為約0.1至約0.2%重量比。
界面活性劑:本發明中有用的組成物可含有陰離子界面活性劑,例如:i.高脂肪酸單甘油酯單硫酸鹽之水溶性鹽類,例如氫化椰油脂肪酸之單硫酸單甘油酯,例如N-甲基N-椰油醯基牛磺酸鈉、椰單甘油酯硫酸鈉,ii.高烷基硫酸鹽,例如月桂基硫酸鈉,iii.高烷基-醚硫酸鹽,例如式CH3(CH2)mCH2(OCH2CH2)nOSO3X之高烷基-醚硫酸鹽,其中m為6-16例如10,n為1-6例如2、3或4,及X為Na或K,例如月桂醇聚醚-2硫酸鈉(CH3(CH2)10CH2(OCH2CH2)2OSO3Na),iv.高烷基芳基磺酸鹽,例如十二烷基苯磺酸鈉(月桂基苯磺酸鈉),v.高烷基磺基乙酸鹽,例如月桂基磺乙酸鈉(十二烷基磺乙酸鈉)、1,2二羥基丙磺酸之高脂肪酸酯、磺基月桂酸鹽(N-2-乙基月桂酸鉀磺基乙醯胺)及月桂基肌胺酸鈉。
「高烷基」係指例如C6-30烷基。在特定的實施例中,陰離子界面活性劑係選自月桂基硫酸鈉及月桂基醚硫酸鈉。陰離子界面活性劑可以調配物的重量計例如>0.01%之有效量存在,但不可為刺激口腔組織之濃度,例如<10%,且最適濃度係依照特定的調配物及特定的界面活性劑而定。例如,所用的濃度或漱口水典型地為用於牙膏的將近十分之一。在一實施例中,陰離子界面活性劑係以從約0.3至約4.5%重量比,例如約1.5%存在於牙膏中。本發明組成物可視需要含有界面活性劑之混合物,例如包含陰離子界面活性劑及其他可為陰離子、陽離子、兩性離子或非離子之界面活性劑。一般而言,界面活性劑為該等在整個廣泛pH範圍中相當穩定之界面活性劑。界面活性劑係更充分地描述於,例如Agricola等人之美國專
利第3,959,458號;Haefele之美國專利第3,937,807號及Gieske等人之美國專利第4,051,234號中。在特定實施例中,可用於本文之陰離子界面活性劑包括在烷基上具有約10至約18個碳原子之烷基硫酸鹽的水溶性鹽類,及具有約10至約18個碳原子之脂肪酸的磺酸化單甘油酯之水溶性鹽類。月桂基硫酸鈉、月桂醯肌胺酸鈉及椰子單甘油酯磺酸鈉為此類陰離子界面活性劑之實例。在一特定的實施例中,本發明組成物,例如組成物1及以下組成物,係包括月桂基硫酸鈉。
界面活性劑或相容的界面活性劑之混合物,可以總組成物的重量計約0.1%至約5.0%存在於本發明組成物中;在另一實施例中為約0.3%至約3.0%重量比,及在另一實施例中為約0.5%至約2.0%重量比。
酒石控制劑:在本發明各種實施例中,組合物係包括一抗結石(酒石控制)劑。適合的抗結石劑包括(不限於)磷酸鹽和聚磷酸鹽(例如焦磷酸鹽)、聚胺基丙磺酸(AMPS)、六偏磷酸鹽、檸檬酸鋅三水合物、多肽、聚烯烴磺酸鹽、聚烯烴磷酸鹽、二磷酸鹽。本發明因此可包括磷酸鹽類。在特定的實施例中,這些鹽類為鹼性磷酸鹽,亦即鹼金屬氫氧化物或鹼土金屬氫氧化物之鹽類,例如鈉鹽、鉀鹽或鈣鹽。「磷酸鹽」如文中所用係涵蓋口腔可接受的單-或聚磷酸鹽,例如P1-6磷酸鹽,例如單體磷酸鹽例如磷酸二氫鹽、磷酸氫鹽或磷酸鹽;二聚磷酸鹽例如焦磷酸鹽;及多聚磷酸鹽,例如六偏磷酸鈉。在特定的實例中,所選的磷酸鹽係選自鹼性磷酸氫鹽和鹼性焦磷酸鹽,例如選自磷酸氫二鈉、磷酸氫二鉀、磷酸二鈣二水合物、焦磷酸鈣、焦磷酸四鈉、焦磷酸四鉀、三聚磷酸鈉及任何二或多種此等之混合物。在特定的實施例中,例如此組成物係包括焦磷酸四鈉(Na4P2O7)、焦磷酸鈣(Ca2P2O7)和磷酸氫二鈉(Na2HPO4)之混合物,例如約3-4%之量的磷酸氫二鈉和約0.2-1%之各焦磷酸鹽。在另外的實施例中,組成物係包括
焦磷酸四鈉(TSPP)和三聚磷酸鈉(STPP)(Na5P3O10)之混合物,例如TSPP為約1-2%及STPP為約7%至約10%之比例。此等磷酸鹽係以有效降低琺瑯質蛀蝕、幫助清潔牙齒及/降低酒石累積在牙齒上之量來提供,例如以組成物之重量計2-20%,例如約5-15%之量。
調味劑:本發明之口腔保健組成物亦可包括調味劑。可用於本發明施行中之調味劑包括(但不限於)精油以及各種調味醛類、酯類、醇類及類似物質。精油之實例包括綠薄荷油、椒薄荷油、冬青油、黄樟油、丁香油、鼠尾草油、尤加利油、馬鬱蘭油、肉桂油、檸檬油、萊姆油、葡萄柚油及柳橙油。亦可使用此等化合物如薄荷醇、香芹酮(carvone)及茴香腦(anethole)。特定實施例係使用椒薄荷油及綠薄荷油。調味劑係以約0.1至約5%重量比,例如約0.5至約1.5%重量比之濃度併入口腔組成物中。
聚合物:本發明之口腔保健組成物亦可包括用以調整調配物黏度或增進其他成份溶解度之另外的聚合物。此等另外的聚合物包括聚乙二醇、多糖類(例如纖維素衍生物,例如羧甲基纖維素,或多糖膠,例如三仙膠或鹿角菜膠)。酸聚合物,例如聚丙烯酸凝膠,可以其游離酸或部分或完全中和的水溶性鹼金屬(例如鉀或鈉)或銨鹽形式來提供。
在水性媒劑中形成聚合結構或凝膠之矽氧增稠劑亦可存在。請注意,這些矽氧增稠劑在物理上和功能上與同樣存在組成物中的顆粒矽氧研磨劑不同,因為矽氧增稠劑為非常細的細粉狀且提供極小或並無研磨作用。其他的增稠劑有羧乙烯基聚合物、鹿角菜膠、羥乙基纖維素及纖維素醚類之水溶性鹽類,例如羧甲基纖維素及羧甲基羥乙基纖維素鈉。亦可併入天然膠例如卡拉膠(karaya)、阿拉伯膠及黄蓍膠。膠體矽酸鎂鋁亦可用作增稠組成物之組份,進一步增進組合物之質地。在特定的實施例中,係使用以總組合物之重量計約0.5%至約5.0%之量的增稠劑。
本發明之組成物可包括,例如從約0.05至約5%之量的陰離子聚合物。此等試劑,雖然並非針對此項之特別應用,但一般已知係用於潔牙劑中,可用於本發明中者係揭示於美國專利第5,188,821號及第5,192,531號中;並包括合成的陰離子聚合性聚羧酸,例如馬來酸酐或酸與另外可聚合的乙烯化不飽和單體之1:4至4:1共聚物,較佳地具有約30,000至約1,000,000,最佳地約30,000至約800,000分子量(M.W.)之甲基乙烯醚/馬來酸酐。這些共聚物可取得的有例如來自ISP Technologies公司(Bound Brook,N.J.08805)之Gantrez如AN 139(M.W.500,000)、AN 119(M.W.250,000)及較佳地S-97醫藥等級(M.W.70,000)。當促進劑存在時,其係以範圍從約0.05至約3%重量比之量存在。其他可施用的聚合物包括該等例如馬來酸酐與丙烯酸乙酯、甲基丙烯酸羥乙基酯、N-乙烯基-2-吡咯酮或乙烯(後者可取得有例如孟山都(Monsanto)EMA編號1103,M.W.10,000及EMA等級61)之1:1共聚物,以及丙烯酸與甲基丙烯酸甲酯或羥乙基酯、丙烯酸甲酯或乙酯、異丁基乙烯醚或N-乙烯基-2-吡咯酮之1:1共聚物。一般適合的為含有一活化碳-碳烯烴雙鍵和至少一羧基基團之聚合烯烴化或乙烯化不飽和羧酸,亦即含有在聚合作用中容易作用之烯烴雙鍵的酸,因為其係以相對於羧基基團之α-β位置或為末端伸甲基基團之部分存在於單體分子中。此等酸之示例有丙烯酸、甲基丙烯酸、乙基丙烯酸、α-氯丙烯酸、巴豆酸、β-丙烯醯氧基丙酸、山梨酸、α-氯山梨酸、肉桂酸、β-苯乙烯基丙烯酸、黏康酸(muconic)、衣康酸(itaconic)、檸康酸(citraconic)、中康酸(mesaconic)、戊烯二酸、烏頭酸、α-苯基丙烯酸、2-苯甲基丙烯酸、2-環己基丙烯酸、當歸酸、傘形酸、延胡索酸、馬來酸及酸酐。可與此等羧酸單體共聚化之其他不同的烯烴單體包括乙烯基乙酸、氯化乙烯、馬來酸二甲酯及其類似物。共聚物含有可溶於水之足夠的羧酸鹽基團。另一類的聚合劑包括含有經取
代丙烯醯胺均聚物及/或不飽和磺酸及其鹽類均聚物之組成物,特別是其中聚合物係以選自丙烯醯胺基烷磺酸之不飽和磺酸為主,例如描述於Zahid之1989年6月27日美國專利第4,842,847號中,具有約1,000至約2,000,000分子量之2-丙烯醯胺2甲基丙磺酸。另外有用的聚合劑種類別包括,例如Sikes等人之美國專利第4,866,161號所揭示之含陰離子表面活化胺基酸部分,如天門冬胺酸、麩胺酸及磷絲胺酸之聚胺基酸。
水:口腔組成物可包括大量的水。用於製備市售口腔組成物的水應去離子化且無有機雜質。組成物中的水量係包括添加的游離水加上隨其他物質例如隨山梨醇或任何本發明組份共同導入的水量。
保濕劑:在特定的口腔組成物之實施例中,亦希望併入一保濕劑以防止組成物因暴露於空氣中而硬化。特定的保濕劑亦可能給予潔牙組成物所欲的甜味或風味。適合的保濕劑包括可食用之多元醇,例如甘油、山梨醇、木糖醇、丙二醇以及其他多醇類與這些保濕劑之混合物。在本發明一實施例中,主要的保濕劑為甘油,其可以大於25%,例如25-35%,約30%之量存在,帶有5%或更少的其他保濕劑。
其他視需要之成份:除了上述組份,本發明之實施例可含有各種某些下述之視需要的潔牙劑成份。視需要的成份包括,例如(但不限於)黏著劑、泡沫劑、調味劑、甜味劑、另外的抗菌斑劑、研磨劑及調色劑。這些及其他視需要組份係進一步描述於Majeti之美國專利第5,004,597號;Agricola等人之美國專利第3,959,458號;Haefele之美國專利第3,937,807號中,其全部係以引用的方式併入本文中。
除非另有說明否則本說明書中所給予的所有組成物組份之百分比係以100%之總組成物或調配物重量為基準之重量比。
除非另有特別說明,否則用於本發明之組成物和調配物中的
成份較佳地為美妝上可接受的成份。「美妝上可接受的」係指適合用於供局部施用於人類皮膚之調配物中。美妝上可接受的賦形劑,例如以本發明組成物中所涵蓋的量和濃度適合外部施用之賦形劑,並包括例如美國食品和藥物管理局之「一般認為是安全的」(GRAS)賦形劑。
文中所提供的組成物和調配係就其成份而言作描述和申請,乃為本項技術中所常見的。熟習本項技術者應可明白,此等成份在某些情況下可能會彼此反應,使得最終調配物之真實組成物可能不會精確的與所列的成份相符。因此,應了解,本發明係延伸至所列成份之組合的產品。
如全文所用,範圍係用於速記供描述在此範圍內的各個和每個值。在此範圍內的任何值皆可選作此範圍的最終值。此外,所有文中所引述的參考文獻其全文係以引用的方式併入本文中。在本揭示文與所引述的參考文獻的定義有衝突時,則以本揭示文為主。
除非另有說明否則文中和說明書之他處所表示的所有百分比和量,應了解係指重量百分比。所給予的量係以物質之有效重量為基準。
形成ZLC之通用反應係如下:ZnO+2(離胺酸.HCl)─›[Zn(離胺酸)2Cl]Cl.2H2O(ZLC)於室溫下攪拌約12小時製備2:1莫耳比之ZnO:離胺酸HCl懸浮液。將混合物離心。將1ml的上清液轉置於NMR試管。然後將NMR試管置入填滿乙醇之封閉的試管中進行晶體生長。一星期後有許多無色、立方晶體形成。以單晶X-光繞射來測定ZLC晶體的結構。此複合物分子之邊長為
1.7nm*7.8nm*4.3nm。在此複合物中,Zn陽離子係藉由二個離胺酸配體與赤道平面之來自NH2基團的二個N原子和來自羧酸基團的O原子配位。其出現了一頂端位置被Cl-原子佔據之扭曲的四方錐幾合形狀。此新穎的結構產生一正陽離子基團,一Cl-陰離子係與其結合而形成離子鹽。
純ZLC粉末之實驗室擴充分析:將2莫耳的離胺酸HCl於室溫攪拌下溶於1000ml DI水,於攪拌下將1莫耳的固體ZnO緩慢地加到離胺酸HCl溶液中並於RT持續攪拌至隔夜(約12小時)。將懸浮溶液以高速離心15分鐘。得到1g粉末大約需要5-8ml EtOH。將帶有粉末的EtOH溶劑過濾,並得到灰白色的粉末。將此粉末置於50℃烘箱中乾燥並得到88%產率之產物。PXRD確認相較於ZLC晶體之ZLC粉末的純度。
以表1所示之成份調配含有NaF、ZLC、ZnCl2和ZnO作為活性成份之四批500g漱口水。本研究的目標係比較不同活性物樣本之透明度。濁度係以TurbiScan®分散穩定性分析儀測量經由溶液之光透射百分比來評估。透射百分比越高,越透明。因此,較小的透射百分比係表示越混濁。以ICP(感應耦合電漿)分析得到的ZLC溶液中之鋅離子濃度為25300ppm,其相當約溶液中17%重量比之ZLC活性物。在所有批件中鋅離子濃度係控制至相同量,亦即1.01重量%。在此四批中,具有ZnO作為活性物之批件顯現乳白色,帶有0%透射度,而其他三個樣本則與去離子水一樣澄清(表2)。
稀釋實驗:將所有原始的漱口水批件稀釋成2倍、4倍、8倍、16倍和32倍。就含NaF、ZLC、ZnCl2和ZnO之漱口水的稀釋液,樣本之濁度數據係分別如表3、4、5和6所示。當ZLC漱口水樣本經稀釋時,觀察到沉澱,但其他樣本的濁度不變。
老化實驗:將經稀釋的ZLC漱口水樣本置於37℃烘箱中過週末(約60小時)進行安定性研究。結果係如表7所示。從4倍的稀釋液開始可觀察到沉澱。在16倍的稀釋液中發現最大量的沉澱。然而,原始的批件仍為安定的且即使在60小時後仍無沉澱出現。
將使用ZnCl2和ZnO調配的漱口水相比較,僅含ZLC作為活性物之調配物可形成澄清、安定的溶液,但當稀釋時產生沉澱。此ZLC漱口水調配物具有中性pH且在37℃為安定的。ZLC提供了儲放時安定但
在稀釋溶液中沉澱之漱口水調配物。藉由稀釋形成不溶性沉澱得以形成牙本質小管中的「阻塞物」,對過敏提供利益。
使用ZLC作為活性成份之前面實例的漱口水調配物不僅顯示可與目前含NaF作為活性成份之市售漱口水產品相競爭的透明度,亦具有當以水稀釋時沉澱的能力。此獨特的性質促進抗過敏和抗齲蝕效用,且其因此在牙膏產品中使用ZLC為有利的。
調配含ZLC作為活性成份之口腔凝膠牙膏並與其他含ZnCl2、ZnO和NaF之調配物作比較。僅ZLC調配物顯現能與目前含NaF凝膠態相競爭的透明度。亦藉由水解反應研究來評估ZLC凝膠態之沉澱性質,提供當牙齒以含ZLC之牙膏刷洗時,在刷洗期間所形成的不溶性粒子可進入牙本質小管並阻斷小管,對消費者產生抗過敏效用和訊號之證據。
以表8所示之成份調配含有NaF(對照)、ZLC、ZnCl2和ZnO作為活性成份之四批500g凝膠態。比較含不同活性物之樣本的透明度,並藉由稀釋評估ZLC凝膠態之沉澱特徵。以ICP得到ZLC溶液中鋅離子之溶度為25300ppm,其給予溶液中大約17%重量比之ZLC活性物。以0.5%(w/w)鋅量製備所有下列各批之鋅離子濃度。
使用Lambda 25 UV/VIS光譜儀(PerkinElmer)得到所有樣本之吸收度資料,以便於比較不同活性物間凝膠態之透明度。吸收度為當通過一物質時,所吸收之光量的對數測量值。因為凝膠中的粒子會吸收光線,因此存在溶液中的粒子越多,被凝膠吸收的光越多。因此,凝膠吸收度的數字小表示透明度越高。吸收度係使用去離子(DI)水作為空白溶液於波長610nm的光源下校正。ZnO不溶解且係懸浮於凝膠態中,產生高吸收度。即使ZnCl2溶於水,含ZnCl2之凝膠態顯現混濁。僅以ZLC調配的凝膠態形成均質的溶液並顯現可與NaF所調配的凝膠態相競爭的透明度。所有樣本的吸收度和pH係如表9所示。
稀釋實驗:將所有原始的凝膠態批件稀釋成2倍、4倍、8倍、16倍和32倍。當NaF凝膠、ZnCl2凝膠和ZnO凝膠進一步稀釋時,吸收度降低,而在進一步稀釋的ZLC凝膠溶液中吸收度增加。此項觀察確定當ZLC凝膠以水稀釋時,形成沉澱。2倍、4倍、8倍、16倍和32倍的稀釋ZLC凝膠溶液之pH分別為7.71、7.91、8.03、8.12和8.14。
上述凝膠可單獨使用或用於具有凝膠態和研磨糊膏態之牙膏中。ZLC作為凝膠態牙膏調配物之活性成份。與以ZnCl2和ZnO所調配的凝膠態批件相比較,僅含ZLC之調配物顯現可與市售產品中所用(NaF作為活性成份)相競爭之透明度和pH。稀釋實驗顯示僅ZLC凝膠態當稀釋時可從透明凝膠形成不可溶沉澱。在使用這類牙膏後,藉由稀釋形成不可溶沉澱促進牙本質小管中形成「阻塞物」,及再者,其在消費者使用期間提供白色沉澱訊號。
相較於無ZLC之口腔凝膠,測量含ZLC之口腔凝膠阻塞牙本質之潛在抗過敏利益。使用Flodec儀器測量通過牙本質小管的液流。使用Pashley cell法(例如Pashley DH,O’Meara JA,Kepler EE,等人Dentin permeability effects of desensitizing dentifrices in vitro.J Periodontol.1984;55(9):522-525)依照S.Mello用於漱口水調配物上測量牙本質阻塞的程序。以吸量管於牙本質盤上以10分鐘間隔用於400μl樣本之二次10分鐘處理。各次處理後,以磷酸緩衝食鹽水(PBS)沖洗牙本質盤並使用FLODEC裝置(一種追蹤毛細管內液面位置,用以測量小量體積變化之裝置)測量流量。表11係顯示含ZLC口腔凝膠之平均流量和樣本施用後流量降低百分比。
表12係顯示在施予樣本後,無ZLC口腔凝膠(對照)的平均流量和流量降低百分比。
相較於無ZLC口腔凝膠(對照),在使用FLODEC裝置之活體外水力傳導模型中,含ZLC口腔凝膠顯示定向上較佳的性能。
製備各種ZLC的稀釋液用以評估其在產生可見沉澱及/或絮凝之效用,其可原位遞送致口腔表面或進入牙齒開口,例如開放的小管。
藉由1)將0.5莫耳的ZnO粉末與1莫耳的離胺酸HCl於1公升的水中在室溫反應約2小時,及2)經由離心收集上清液,接著使用0.45
微米膜進行過濾,製備ZLC純溶液。此純溶液具有2.39%重量比之鋅濃度,及約7.03之pH。
稀釋實驗係藉由將純溶液與去離子水混合來進行。純溶液係稀釋成2x、4x、6x、7x、8x、10x、12x、16x、20x、24x、28x和32x,分別相當1.20%、0.598%、0.398%、0.341%、0.299%、0.239%、0.199%、0.149%、0.120%、0.0996%、0.0854%、0.0747%重量比之起始鋅濃度。將稀釋的樣本放置在37℃,並監測絮凝/沉澱發生之速率。從儲存溶液與水混合之時間點起30分鐘內,0.149%和0.199%之起始鋅濃度的稀釋液能產生可見的絮凝。混合1小時,在含起始鋅濃度介於0.0854%至0.239%間的稀釋液中觀察到可見絮凝。混合後1個半小時,在含起始鋅濃度介於0.0747%至0.239%間的稀釋液中觀察到可見絮凝。混合後2小時,在含起始鋅濃度0.299%的稀釋液中亦顯示有絮凝存在。總計19小時後,除了含起始鋅濃度1.20%的稀釋液,在所有的樣本中皆觀察到絮凝及/或沉澱,且含起始鋅濃度0.0747%至0.239%間的稀釋液具有最多沉澱。
最終經稀釋樣本之pH值適合口腔保健應用。含起始鋅濃度0.0747%、0.0854%、0.0996%、0.120%、0.149%、0.199重量%和0.239%之樣本分別具有7.99、8.13、8.11、7.97、7.99、6.80和6.70之最終pH值。這些pH值完全在定義口腔保健調配物之適合範圍5.5至10的範圍內。
鋅主要係以氧化鋅之形式存在沉澱物中。離胺酸係以其整合組份及/或為雜質存在沉澱中。
於可形成可見沉澱之條件下,以共軛焦顯影驗證ZLC在產生表面沉澱及於牙本質表面上阻塞小管開口之效用。
沉積/阻塞分析係使用人類牙本質切片及實例5之純溶液來進行。牙本質切片係藉由將人類的牙齒切成大約800微米厚度之牙本質薄片,選擇一試驗側,使用約600粒度的砂紙打磨該試驗側,使用Buehler拋光布及5微米Buehler氧化鋁拋光該試驗側,以1%(重量比)檸檬酸溶液酸蝕該牙本質切片約20秒,以超音波處理該牙本質切片10分鐘,並將該牙本質切片儲存於磷酸緩衝食鹽水中(PBS,pH 7.4)。
就處理,係將純溶液以水稀釋16-倍,產生含起始鋅溶度約0.149%重量比之處理溶液。將牙本質切片於37℃浸入處理溶液中1小時。然後將經處理的牙本質切片從處理溶液中移出,每次以各1mL的PBS沖洗4次。然後使用紙巾乾燥並於共軛焦顯微鏡下以XYZ和XYZ二種模式檢查。後續的處理係以相同的方式來進行。
經由共軛焦顯影可觀察到漸進的沉積和阻塞。第一次處理造成顯著的沉積。第二次處理造成完全覆蓋表面,包括阻斷實質上所有的小管開口。表面沉積厚度可能為10微米或更大。第三次處理後,觀察到表面完全覆蓋及阻斷小管開口。表面沉積厚度可能為25微米或更大。此沉積使牙本質表面為白色。
表面沉積提供各種利益,包括該等常見與鋅和離胺酸有關的利益,以及經由以沉積中和蛀蝕性酸保護免於蛀蝕,經由阻斷小管免於過敏及由於從沉積物逐漸釋放鋅和離胺酸之控制性釋放活性物,特別是因酸挑戰。
於未觀察到可見沉澱之條件下,以共軛焦顯影驗證ZLC在產生表面沉澱及於牙本質表面上阻塞小管開口之效用。
如實例6製備牙本質切片,重複以含起始鋅濃度0.0747%重量比之ZLC稀釋液處理。各處理包括32mL的稀釋溶液(1mL之來自實例5的純溶液和31mL的去離子水)並於37℃持續至少10分鐘,在此期間以肉眼並未觀察到沉澱。於每次處理後於共軛焦顯微鏡下檢查牙本質切片。連續4次處理後,觀察到顯著的表面沉積。12次連續處理後,觀察到表面完全覆蓋而無小管開口存在之跡象。
因此,表面沉積和小管阻塞可在無產生可見沉澱之依據稀釋比例和處理效期條件下發生。
如表13(下表)所述製備包括鋅-離胺酸、1450ppm氟化物和磷酸鹽之試驗的潔牙劑。
當本發明係就相關特定的實例,包括目前進行本發明之較佳模式來描述時,熟習本項技術者應了解,上述系統和技術有許多變化和變更。應了解,可利用其他實施例且在不悖離本發明範圍內可做結構和功能修改。因此,本發明之範圍應廣泛地理解為如所附的申請專利範圍中所述。
Claims (18)
- 一種潔牙劑,包括鋅胺基酸鹵化物。
- 如申請專利範圍第1項之潔牙劑,其中該鋅胺基酸鹵化物係由前驅物所形成。
- 如申請專利範圍第2項之潔牙劑,且其中該前驅物為鋅離子來源、胺基酸來源和鹵化物來源。
- 如申請專利範圍第2或3項之潔牙劑,其中該鹵化物來源可為鋅離子來源、胺基酸來源或鹵酸來源之一部分。
- 如前述申請專利範圍中任一項之潔牙劑,其中該胺基酸係選自游離或口腔可接受酸加成鹽形式之離胺酸、甘胺酸和精胺酸。
- 如前述申請專利範圍中任一項之潔牙劑,其中該胺基酸為游離或口腔可接受鹽形式之鹼性胺基酸。
- 如前述申請專利範圍中任一項之潔牙劑,其中鋅量為0.05-4%重量比。
- 如前述申請專利範圍中任一項之潔牙劑,其中該鋅離子來源和胺基酸來源係為一複合物。
- 如前述申請專利範圍中任一項之潔牙劑,其中該鋅為已溶解的,使得凝膠實質上為澄清的,其在使用和以唾液稀釋及/或沖洗後提供鋅離子沉澱。
- 如前述申請專利範圍中任一項之潔牙劑,其中該鋅離子和胺基酸係形成一鋅離胺酸氯化物複合物或鋅精胺酸氯化物複合物。
- 如前述申請專利範圍中任一項之潔牙劑,其中該鋅胺基酸複合物為具有化學結構[Zn(C6H14N2O2)2Cl]+ Cl-之鋅離胺酸氯化物複合物,其係為陽離子性陽離子(例如[Zn(C6H14N2O2)2Cl]+)和氯陰離子之溶液,或為固體鹽形式,視需要單或二-水合物形式。
- 如前述申請專利範圍中任一項之潔牙劑,其進一步包括一有效量之氟化物離子來源。
- 如前述申請專利範圍中任一項之潔牙劑,係包括一包含選自下列成份之口腔可接受的基底:一或多種研磨劑、緩衝劑、保濕劑、界面活性劑、增稠劑、膠條或膠片、口氣清新劑、調味劑、香精、調色劑、抗細菌劑、增白劑、干擾和預防細菌黏附之試劑、鈣來源、磷酸鹽來源、口腔可接受的鉀鹽和陰離子聚合物。
- 如前述申請專利範圍中任一項之潔牙劑,其中該凝膠的pH係從pH 6至pH 8。
- 如前述申請專利範圍中任一項之潔牙劑,係用於降低和抑制琺瑯質酸蝕、清潔牙齒、降低細菌產生的生物膜和牙菌斑、降低牙齦炎、抑制牙齒齲蝕和形成蛀洞及/或降低牙本質過敏。
- 如前述申請專利範圍中任一項之潔牙劑,其中該潔牙劑為一實質上澄清的凝膠。
- 一種鋅離子與胺基酸共同為一複合物之用途,係用於製造潔牙劑。
- 一種如申請專利範圍第1至16項中任一項之潔牙劑、及視需要足以引發氧化鋅從凝膠沉澱之水或水溶液之用途,係用於製造口腔保健產品供治療或降低琺瑯質酸蝕、清潔牙齒、降低細菌產生的生物膜和牙菌斑、降低牙齦炎、抑制牙齒齲蝕和形成蛀洞以及/或降低牙本質過敏。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/070513 WO2014098824A1 (en) | 2012-12-19 | 2012-12-19 | Oral gel comprising zinc - amino acid complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201424762A true TW201424762A (zh) | 2014-07-01 |
| TWI522120B TWI522120B (zh) | 2016-02-21 |
Family
ID=47501517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103136089A TW201526919A (zh) | 2012-12-19 | 2013-11-28 | 包含鋅-胺基酸複合物的口腔用凝膠 |
| TW102143368A TWI522120B (zh) | 2012-12-19 | 2013-11-28 | 包含鋅-胺基酸複合物的口腔用凝膠 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103136089A TW201526919A (zh) | 2012-12-19 | 2013-11-28 | 包含鋅-胺基酸複合物的口腔用凝膠 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9763865B2 (zh) |
| EP (1) | EP2934441B1 (zh) |
| KR (1) | KR20150094651A (zh) |
| CN (1) | CN104853723B (zh) |
| AR (1) | AR094075A1 (zh) |
| AU (1) | AU2012397265B2 (zh) |
| BR (1) | BR112015014900B1 (zh) |
| CA (1) | CA2892419C (zh) |
| IL (1) | IL239530A0 (zh) |
| MX (1) | MX368740B (zh) |
| PH (1) | PH12015501436B1 (zh) |
| RU (1) | RU2636226C2 (zh) |
| TW (2) | TW201526919A (zh) |
| WO (1) | WO2014098824A1 (zh) |
| ZA (1) | ZA201503848B (zh) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352357B (es) | 2012-12-19 | 2017-11-22 | Colgate Palmolive Co | Productos para el cuidado oral que contienen un complejo de zinc tetrabásico-aminoácido-halogenuro. |
| US9504858B2 (en) | 2012-12-19 | 2016-11-29 | Colgate-Palmolive Company | Zinc amino acid halide complex with cysteine |
| AU2012397270B9 (en) | 2012-12-19 | 2015-08-13 | Colgate-Palmolive Company | Oral care products comprising zinc oxide and trimethylglycine |
| BR112015014502B1 (pt) * | 2012-12-19 | 2019-04-09 | Colgate-Palmolive Company | Composição para cuidado oral compreendendo um complexo haleto de aminoácido-zinco e usos da mesma |
| CA2892468C (en) | 2012-12-19 | 2019-10-08 | Colgate-Palmolive Company | Oral care products comprising tetrabasic zinc chloride and trimethylglycine |
| US9675823B2 (en) | 2012-12-19 | 2017-06-13 | Colgate-Palmolive Company | Two component compositions containing zinc amino acid halide complexes and cysteine |
| RU2627840C2 (ru) | 2012-12-19 | 2017-08-14 | Колгейт-Палмолив Компани | Антиперспирантные продукты с содержанием белка и антиперспирантных солей |
| US10188112B2 (en) | 2012-12-19 | 2019-01-29 | Colgate-Palmolive Company | Personal cleansing compositions containing zinc amino acid/trimethylglycine halide |
| JP5968558B2 (ja) * | 2012-12-19 | 2016-08-10 | コルゲート・パーモリブ・カンパニーColgate−Palmolive Company | 亜鉛リジン錯体 |
| US20190104741A1 (en) * | 2012-12-19 | 2019-04-11 | Colgate-Palmolive Company | Personal Cleansing Compositions Containing Zinc Amino Acid / Trimethylglycine Halide |
| CN104853721B (zh) | 2012-12-19 | 2017-10-27 | 高露洁-棕榄公司 | 锌精氨酸/赖氨酸卤化物 |
| AU2012397263B2 (en) | 2012-12-19 | 2015-09-24 | Colgate-Palmolive Company | Zinc amino acid halide mouthwashes |
| RU2638791C2 (ru) | 2012-12-19 | 2017-12-15 | Колгейт-Палмолив Компани | Композиция с галогенидными предшественниками аминокислоты/триметилглицина цинка |
| US9750670B2 (en) | 2012-12-19 | 2017-09-05 | Colgate-Palmolive Company | Zinc amino acid complex with cysteine |
| US9763865B2 (en) * | 2012-12-19 | 2017-09-19 | Colgate-Palmolive Company | Oral gel comprising zinc-amino acid complex |
| US9498421B2 (en) | 2012-12-19 | 2016-11-22 | Colgate-Palmolive Company | Two component compositions containing tetrabasic zinc-amino acid halide complexes and cysteine |
| WO2014098828A1 (en) | 2012-12-19 | 2014-06-26 | Colgate-Palmolive Company | Teeth whitening methods, visually perceptible signals and compositions therefor|comprising zinc amino acid halides |
| WO2015195124A1 (en) | 2014-06-18 | 2015-12-23 | Colgate-Palmolive Company | Dentifrice comprising zinc - amino acid complex and phosphates |
| CN106459094B (zh) | 2014-06-18 | 2019-07-16 | 高露洁-棕榄公司 | 锌-赖氨酸络合物的低pH合成 |
| EP3157935B1 (en) | 2014-06-18 | 2018-08-15 | Colgate-Palmolive Company | Synthesis of zinc-lysine complex from zinc chloride |
| EP3233205B1 (en) | 2014-12-26 | 2019-09-25 | Colgate-Palmolive Company | Zinc phosphate complex |
| RU2690191C2 (ru) | 2014-12-26 | 2019-05-31 | Колгейт-Палмолив Компани | Комплекс фосфата цинка |
| MX376016B (es) | 2014-12-26 | 2025-03-07 | Colgate Palmolive Co | Composiciones para el cuidado personal con activo de fosfato de zinc. |
| WO2016105429A1 (en) | 2014-12-26 | 2016-06-30 | Colgate-Palmolive Company | Zinc phosphate complex |
| US20170157013A1 (en) * | 2015-12-07 | 2017-06-08 | Colgate-Palmolive Company | Metal Amino Acid Complexes for Bacterial Aggregation |
| MX2018008569A (es) | 2016-01-28 | 2018-08-16 | Kimberly Clark Co | Composicion antiadherente contra virus de acido desoxirribonucleico (adn) y metodo para inhibir la adherencia de virus de acido desoxirribonucleico (adn) a una superficie. |
| AU2016408394B2 (en) | 2016-05-26 | 2021-11-11 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| US10058493B2 (en) | 2016-12-21 | 2018-08-28 | Colgate-Palmolive Company | Oral care compositions and methods of use |
| US10485742B2 (en) * | 2017-12-01 | 2019-11-26 | Colgate-Palmolive Company | Rheological stabilization through mixed humectant systems in a zinc toothpaste |
| US11186489B2 (en) | 2017-12-05 | 2021-11-30 | Colgate-Palmolive Company | Zinc / amino acid-functionalized silica |
| AU2017442633C1 (en) * | 2017-12-13 | 2021-12-23 | Colgate-Palmolive Company | Dentifrice comprising zinc - amino acid complex |
| US10532016B2 (en) * | 2017-12-13 | 2020-01-14 | Colgate-Palmolive Company | Zinc-amino acid-tripolyphosphate complexes |
| CN112839623A (zh) | 2018-10-24 | 2021-05-25 | 高露洁-棕榄公司 | 具有抗微生物活性的锌-氨基酸-月桂基硫酸盐络合物 |
| EP3880192A1 (en) | 2018-12-20 | 2021-09-22 | Colgate-Palmolive Company | Oral care composition comprising zinc and an amino acid for treating symptoms of a gastric disorder in the oral cavity |
| US11229591B2 (en) | 2018-12-21 | 2022-01-25 | Colgate-Palmolive Company | Methods for synthesizing zinc-lysine-chloride complex |
| EP3897864A1 (en) | 2018-12-21 | 2021-10-27 | Colgate-Palmolive Company | Zinc-arginine-halide complex |
| US11091502B2 (en) | 2018-12-21 | 2021-08-17 | Colgate-Palmolive Company | Methods for synthesizing zinc-lysine-chloride complex |
| US11117906B2 (en) | 2018-12-21 | 2021-09-14 | Colgate-Palmolive Company | Methods for synthesizing zinc-lysine-chloride complex |
| US12428609B2 (en) * | 2019-11-27 | 2025-09-30 | International Flavors & Fragrances Inc. | Organoleptic compounds |
| CN120884496A (zh) * | 2019-12-31 | 2025-11-04 | 舒万诺知识产权公司 | 具有氟化物的水性锌口腔护理组合物 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE735096C (de) | 1940-12-09 | 1943-05-06 | Ig Farbenindustrie Ag | Verfahren zur Herstellung von Sulfonsaeuren |
| US2527686A (en) | 1945-12-26 | 1950-10-31 | Max H Sandberg | Mouthwash |
| US2503280A (en) | 1947-10-24 | 1950-04-11 | Du Pont | Azo catalysts in preparation of sulfonic acids |
| US2507088A (en) | 1948-01-08 | 1950-05-09 | Du Pont | Sulfoxidation process |
| US2893918A (en) | 1957-04-24 | 1959-07-07 | Harold A Abramson | Deodorant composition |
| FR1247957A (fr) | 1958-09-28 | 1960-12-09 | Ajinomoto Kk | Procédé de séparation continue d'aminoacides racémiques |
| US3320174A (en) | 1964-04-20 | 1967-05-16 | Colgate Palmolive Co | Detergent composition |
| US3372188A (en) | 1965-03-12 | 1968-03-05 | Union Oil Co | Sulfoxidation process in the presence of sulfur trioxide |
| US3538230A (en) | 1966-12-05 | 1970-11-03 | Lever Brothers Ltd | Oral compositions containing silica xerogels as cleaning and polishing agents |
| US3678154A (en) | 1968-07-01 | 1972-07-18 | Procter & Gamble | Oral compositions for calculus retardation |
| US3535421A (en) | 1968-07-11 | 1970-10-20 | Procter & Gamble | Oral compositions for calculus retardation |
| US3741911A (en) | 1970-12-21 | 1973-06-26 | Hart Chemical Ltd | Phosphate-free detergent composition |
| US3959458A (en) | 1973-02-09 | 1976-05-25 | The Procter & Gamble Company | Oral compositions for calculus retardation |
| US3937807A (en) | 1973-03-06 | 1976-02-10 | The Procter & Gamble Company | Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies |
| US3862307A (en) | 1973-04-09 | 1975-01-21 | Procter & Gamble | Dentifrices containing a cationic therapeutic agent and improved silica abrasive |
| US3941818A (en) | 1973-08-20 | 1976-03-02 | Zinpro Corporation | 1:1 Zinc methionine complexes |
| US4039681A (en) * | 1973-08-20 | 1977-08-02 | Zinpro Corporation | Zinc methionine complex for acne treatment |
| US4051234A (en) | 1975-06-06 | 1977-09-27 | The Procter & Gamble Company | Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies |
| US4340583A (en) | 1979-05-23 | 1982-07-20 | J. M. Huber Corporation | High fluoride compatibility dentifrice abrasives and compositions |
| US4339432A (en) | 1979-06-20 | 1982-07-13 | Lever Brothers Company | Oral mouthwash containing zinc and glycine |
| CA1139229A (en) * | 1979-06-20 | 1983-01-11 | Thomas W. Ritchey | Zinc salt with glycine in oral composition |
| US4316824A (en) | 1980-06-26 | 1982-02-23 | The Procter & Gamble Company | Liquid detergent composition containing alkyl sulfate and alkyl ethoxylated sulfate |
| JPS57158724A (en) * | 1981-03-26 | 1982-09-30 | Shiseido Co Ltd | Antimicrobial composition |
| US4565693A (en) | 1981-11-09 | 1986-01-21 | Colgate-Palmolive Company | Deodorant composition |
| US4487757A (en) | 1981-12-28 | 1984-12-11 | Colgate-Palmolive Company | Dispensing container of toothpaste which effervesces during toothbrushing |
| IL64700A0 (en) | 1982-01-01 | 1982-03-31 | Binderman Itzhak | Dental care compositions |
| US4885155A (en) | 1982-06-22 | 1989-12-05 | The Procter & Gamble Company | Anticalculus compositions using pyrophosphate salt |
| DE3238118A1 (de) * | 1982-10-14 | 1984-04-19 | Verla-Pharm, Arzneimittelfabrik Apotheker H.J. v. Ehrlich GmbH & Co KG, 8132 Tutzing | Verfahren zur herstellung von komplexverbindungen aus aminodicarbonsaeuren, zweiwertigen metallionen und halogenidionen |
| US4687663B1 (en) | 1983-03-01 | 1997-10-07 | Chesebrough Ponds Usa Co | Dental preparation article and method for storage and delivery thereof |
| US4684528A (en) | 1984-06-11 | 1987-08-04 | Godfrey Science & Design, Inc. | Flavor of zinc supplements for oral use |
| US4599152A (en) | 1985-05-24 | 1986-07-08 | Albion Laboratories | Pure amino acid chelates |
| US5192531A (en) | 1988-12-29 | 1993-03-09 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
| US5188821A (en) | 1987-01-30 | 1993-02-23 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition mouthwash or liquid dentifrice |
| US4866161A (en) | 1987-08-24 | 1989-09-12 | University Of South Alabama | Inhibition of tartar deposition by polyanionic/hydrophobic peptides and derivatives thereof which have a clustered block copolymer structure |
| US5004597A (en) | 1987-09-14 | 1991-04-02 | The Procter & Gamble Company | Oral compositions comprising stannous flouride and stannous gluconate |
| US4842847A (en) | 1987-12-21 | 1989-06-27 | The B. F. Goodrich Company | Dental calculus inhibiting compositions |
| US5061815A (en) | 1988-07-06 | 1991-10-29 | Zinpro Corporation | Metal lysine complexes and method for producing metal lysine complexes |
| US5156845A (en) | 1990-05-04 | 1992-10-20 | Colgate-Palmolive Company | Dry mouth lozenge |
| GB2243775A (en) | 1990-05-09 | 1991-11-13 | Unilever Plc | Oral compositions |
| JPH0578243A (ja) | 1990-12-11 | 1993-03-30 | Shiseido Co Ltd | 鎮痒剤及び鎮痒組成物 |
| GB9107833D0 (en) | 1991-04-12 | 1991-05-29 | Unilever Plc | Treatment of periodontitis |
| US5643559A (en) | 1991-10-30 | 1997-07-01 | Colgate-Palmolive Company | Deodorant compositions comprising inhibitors of odor-producing axillary bacterial exoenzymes |
| US5504055A (en) | 1994-03-15 | 1996-04-02 | J.H. Biotech, Inc. | Metal amino acid chelate |
| US5707679A (en) | 1994-09-30 | 1998-01-13 | Kemin Industries, Inc. | Metal propionates for use as animal feed supplements |
| EP1203575B1 (en) | 1995-05-03 | 2010-09-01 | Unilever N.V. | Clear gel-type dentrifices |
| US5714447A (en) | 1996-01-24 | 1998-02-03 | Church & Dwight Co., Inc. | Deodorant soap or detergent composition containing a zinc compound and a polyamine |
| US5698724A (en) | 1996-04-30 | 1997-12-16 | Zinpro Corporation | Amino acid metal complexes using hydrolyzed protein as the amino acid source and methods re same |
| AU4428397A (en) | 1996-09-20 | 1998-04-14 | Warner-Lambert Company | Oral compositions containing a zinc compound |
| GB9622659D0 (en) | 1996-10-31 | 1997-01-08 | Unilever Plc | Hair treatment composition |
| US5897891A (en) | 1996-11-18 | 1999-04-27 | Godfrey; John C. | Flavorful zinc compositions for oral use incorporating copper |
| FI106923B (fi) | 1997-01-03 | 2001-05-15 | Cultor Ltd Finnsugar Bioproduc | Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa |
| US5993784A (en) | 1997-07-24 | 1999-11-30 | Whitehill Oral Technologies | Low foaming therapeutic toothpastes with improved cleaning and abrasion performance |
| DK176196B1 (da) | 1997-10-07 | 2007-01-08 | Ejvind Jersie Pedersen | Mundhygejnepræparat til behandling af halitosis samt anvendelse af et chelat omfattende en metaliondel og en aminosyredel som en komponent i præparatet |
| JP2002517411A (ja) | 1998-06-09 | 2002-06-18 | ウイリアム ジェイ エンブロ | 表皮刺激及び感染の治療のための方法並びに組成物 |
| US6169118B1 (en) * | 1998-11-12 | 2001-01-02 | Block Drug Company, Inc. | Flavor blend for masking unpleasant taste of zinc compounds |
| US6558710B1 (en) | 1999-06-14 | 2003-05-06 | Helen Rebecca Godfrey | Topical zinc compositions and methods of use |
| US6685920B2 (en) | 1999-11-12 | 2004-02-03 | The Procter & Gamble Company | Method of protecting teeth against erosion |
| US7164035B2 (en) | 2000-01-07 | 2007-01-16 | Newsome David A | Zinc-monocysteine complex and method of using zinc-cysteine complexes |
| JP3490950B2 (ja) | 2000-03-15 | 2004-01-26 | 三洋電機株式会社 | 2シリンダ型2段圧縮式ロータリーコンプレッサ |
| DE10160933B4 (de) | 2001-12-12 | 2018-06-21 | Evonik Degussa Gmbh | Zubereitungen mit desodorierender Wirkung, enthaltend das Zinksalz der Ricinolsäure und mindestens eine aminofunktionelle Aminosäure |
| US6670494B1 (en) | 2001-12-17 | 2003-12-30 | J H Brotech, Inc. | Method for preparation of metal organic acid chelates |
| US20040033916A1 (en) | 2002-06-28 | 2004-02-19 | Kuzmin Vladimir Semenovich | Disinfecting composition |
| JP2004175790A (ja) * | 2002-11-12 | 2004-06-24 | Arita Junichi | α−グルコシダーゼ阻害作用を有する亜鉛含有物 |
| US7022351B2 (en) | 2003-01-14 | 2006-04-04 | Zinpro Corporation | Composition for supplementing animals with solutions of essential metal amino acid complexes |
| US20040198998A1 (en) | 2003-04-04 | 2004-10-07 | Marian Holerca | Glycine-free antiperspirant salts with betaine for enhanced cosmetic products |
| US7270806B2 (en) | 2004-07-27 | 2007-09-18 | Coty S.A. | Liquid stick antiperspirant |
| US7700079B2 (en) | 2005-09-26 | 2010-04-20 | Jamie Collins Doss | Therapeutic soap product with UV protection |
| CA2631254A1 (en) | 2005-11-29 | 2007-06-07 | The Procter & Gamble Company | Dentifrice composition comprising binder system comprising hydrophilic clay material |
| CN100366539C (zh) | 2006-05-25 | 2008-02-06 | 黄逸强 | 一种微量元素添加剂碱式氯化锌的制备方法 |
| DE102006040302A1 (de) | 2006-08-29 | 2008-03-20 | Henkel Kgaa | Antitranspirant- und Deodorant-Zusammensetzungen mit verbesserter Pflegewirkung |
| EP1935395B1 (en) | 2006-12-20 | 2013-06-05 | Unilever PLC | Oral composition |
| US8247398B2 (en) | 2007-02-17 | 2012-08-21 | Ssv Therapeutics, Inc. | Zinc complexes of natural amino acids for treating elevated copper caused toxicities |
| JP2009084201A (ja) | 2007-09-28 | 2009-04-23 | Riken Koryo Kogyo Kk | パーマネントウェーブ剤用消臭処理剤並びにこれを含有するパーマネントウェーブ剤 |
| CN101172956A (zh) * | 2007-10-26 | 2008-05-07 | 白家强 | 单体赖氨酸锌及再转为赖氨酸锌络合物的制备和用途 |
| US20110229536A1 (en) | 2008-05-12 | 2011-09-22 | Tagra Biotechnologies Ltd. | Compositions for topical application comprising microencapsulated colorants |
| US20100021573A1 (en) | 2008-07-22 | 2010-01-28 | Michael J Gonzalez | Compositions and methods for the prevention of cardiovascular disease |
| JP2010132639A (ja) | 2008-11-10 | 2010-06-17 | Nikko Chemical Co Ltd | Dna損傷抑制剤及びマトリックスメタロプロテアーゼ−1産生抑制剤 |
| RU2540520C2 (ru) | 2009-06-24 | 2015-02-10 | Чарльз Н.С. СОПАРКАР | Композиции и способы улучшения медикаментозной терапии средствами, зависящими от ионов металлов |
| CN101606639B (zh) | 2009-07-20 | 2012-07-25 | 曹江山 | 一种保育猪浓缩饲料 |
| RU2491912C1 (ru) | 2009-09-30 | 2013-09-10 | Колгейт-Палмолив Компани | Композиция антиперспиранта/дезодоранта |
| RU2523900C2 (ru) | 2009-10-29 | 2014-07-27 | Колгейт-Палмолив Компани | Средство для чистки зубов, содержащее фторид двухвалентного олова и цитрат цинка и небольшие количества воды |
| AR079890A1 (es) | 2010-01-13 | 2012-02-29 | Colgate Palmolive Co | Estabilizacion de peliculas de oxido de zinc en composiciones bucales |
| US8652495B2 (en) * | 2010-03-31 | 2014-02-18 | Colgate-Palmolive Company | Oral care composition |
| CN103156073B (zh) | 2011-12-13 | 2015-02-18 | 北京东方联鸣科技发展有限公司 | 奶牛产后营养补充剂 |
| CN103535536A (zh) | 2012-07-15 | 2014-01-29 | 新沂市佳威饲料有限公司 | 一种哺乳母猪饲料的配制方法 |
| EP2928440B2 (en) | 2012-12-05 | 2019-12-18 | Colgate-Palmolive Company | Fluoride-stable zinc containing oral care compositions |
| IN2015DN03993A (zh) | 2012-12-06 | 2015-10-02 | Colgate Palmolive Co | |
| JP5968558B2 (ja) * | 2012-12-19 | 2016-08-10 | コルゲート・パーモリブ・カンパニーColgate−Palmolive Company | 亜鉛リジン錯体 |
| US9763865B2 (en) * | 2012-12-19 | 2017-09-19 | Colgate-Palmolive Company | Oral gel comprising zinc-amino acid complex |
| AU2012397263B2 (en) | 2012-12-19 | 2015-09-24 | Colgate-Palmolive Company | Zinc amino acid halide mouthwashes |
| BR112015014502B1 (pt) | 2012-12-19 | 2019-04-09 | Colgate-Palmolive Company | Composição para cuidado oral compreendendo um complexo haleto de aminoácido-zinco e usos da mesma |
| WO2014204439A1 (en) | 2013-06-18 | 2014-12-24 | Colgate-Palmolive Company | Zinc amino acid halide complex with cysteine |
| WO2014098821A1 (en) | 2012-12-19 | 2014-06-26 | Colgate-Palmolive Company | Method for indicating time for washing or indicating delivery of antibacterial agent |
| CN104853721B (zh) | 2012-12-19 | 2017-10-27 | 高露洁-棕榄公司 | 锌精氨酸/赖氨酸卤化物 |
| RU2638791C2 (ru) | 2012-12-19 | 2017-12-15 | Колгейт-Палмолив Компани | Композиция с галогенидными предшественниками аминокислоты/триметилглицина цинка |
| US9675823B2 (en) * | 2012-12-19 | 2017-06-13 | Colgate-Palmolive Company | Two component compositions containing zinc amino acid halide complexes and cysteine |
| RU2627840C2 (ru) | 2012-12-19 | 2017-08-14 | Колгейт-Палмолив Компани | Антиперспирантные продукты с содержанием белка и антиперспирантных солей |
| CA2892468C (en) | 2012-12-19 | 2019-10-08 | Colgate-Palmolive Company | Oral care products comprising tetrabasic zinc chloride and trimethylglycine |
| WO2014098828A1 (en) | 2012-12-19 | 2014-06-26 | Colgate-Palmolive Company | Teeth whitening methods, visually perceptible signals and compositions therefor|comprising zinc amino acid halides |
| AU2012397270B9 (en) | 2012-12-19 | 2015-08-13 | Colgate-Palmolive Company | Oral care products comprising zinc oxide and trimethylglycine |
| US10494589B2 (en) | 2012-12-19 | 2019-12-03 | Colgate-Palmolive Company | Method for indicating time for washing or indicating delivery of antibacterial agent |
| MX352357B (es) * | 2012-12-19 | 2017-11-22 | Colgate Palmolive Co | Productos para el cuidado oral que contienen un complejo de zinc tetrabásico-aminoácido-halogenuro. |
| IN2015DN04211A (zh) | 2012-12-19 | 2015-10-16 | Colgate Palmolive Co | |
| WO2015195124A1 (en) * | 2014-06-18 | 2015-12-23 | Colgate-Palmolive Company | Dentifrice comprising zinc - amino acid complex and phosphates |
| US9913784B2 (en) * | 2015-12-22 | 2018-03-13 | Colgate-Palmolive Company | Oral care compositions comprising zinc amino acid halides |
-
2012
- 2012-12-19 US US14/653,880 patent/US9763865B2/en active Active
- 2012-12-19 KR KR1020157016635A patent/KR20150094651A/ko not_active Withdrawn
- 2012-12-19 AU AU2012397265A patent/AU2012397265B2/en active Active
- 2012-12-19 CA CA2892419A patent/CA2892419C/en active Active
- 2012-12-19 RU RU2015123653A patent/RU2636226C2/ru active
- 2012-12-19 EP EP12809989.2A patent/EP2934441B1/en active Active
- 2012-12-19 MX MX2015007980A patent/MX368740B/es active IP Right Grant
- 2012-12-19 BR BR112015014900-6A patent/BR112015014900B1/pt active IP Right Grant
- 2012-12-19 WO PCT/US2012/070513 patent/WO2014098824A1/en not_active Ceased
- 2012-12-19 PH PH1/2015/501436A patent/PH12015501436B1/en unknown
- 2012-12-19 CN CN201280077876.5A patent/CN104853723B/zh active Active
-
2013
- 2013-11-28 TW TW103136089A patent/TW201526919A/zh unknown
- 2013-11-28 TW TW102143368A patent/TWI522120B/zh not_active IP Right Cessation
- 2013-12-17 AR ARP130104809A patent/AR094075A1/es unknown
-
2015
- 2015-05-28 ZA ZA2015/03848A patent/ZA201503848B/en unknown
- 2015-06-18 IL IL239530A patent/IL239530A0/en unknown
-
2017
- 2017-08-11 US US15/674,557 patent/US10245222B2/en active Active
-
2019
- 2019-02-25 US US16/284,668 patent/US10792236B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012397265B2 (en) | 2016-02-25 |
| ZA201503848B (en) | 2017-07-26 |
| PH12015501436A1 (en) | 2015-09-14 |
| IL239530A0 (en) | 2015-08-31 |
| CN104853723A (zh) | 2015-08-19 |
| PH12015501436B1 (en) | 2022-07-01 |
| RU2015123653A (ru) | 2017-01-25 |
| MX368740B (es) | 2019-10-14 |
| RU2636226C2 (ru) | 2017-11-21 |
| EP2934441B1 (en) | 2017-04-26 |
| TWI522120B (zh) | 2016-02-21 |
| US20150328110A1 (en) | 2015-11-19 |
| BR112015014900B1 (pt) | 2019-05-14 |
| US9763865B2 (en) | 2017-09-19 |
| MX2015007980A (es) | 2015-10-22 |
| TW201526919A (zh) | 2015-07-16 |
| EP2934441A1 (en) | 2015-10-28 |
| US10245222B2 (en) | 2019-04-02 |
| CA2892419C (en) | 2019-09-17 |
| US10792236B2 (en) | 2020-10-06 |
| WO2014098824A1 (en) | 2014-06-26 |
| US20170340539A1 (en) | 2017-11-30 |
| CN104853723B (zh) | 2017-12-08 |
| BR112015014900A2 (pt) | 2017-07-11 |
| KR20150094651A (ko) | 2015-08-19 |
| AR094075A1 (es) | 2015-07-08 |
| CA2892419A1 (en) | 2014-06-26 |
| AU2012397265A1 (en) | 2015-06-18 |
| US20190183766A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI522120B (zh) | 包含鋅-胺基酸複合物的口腔用凝膠 | |
| TWI555534B (zh) | 含四鹼基鋅-胺基酸-鹵化物複合物之口腔保健產品 | |
| CN104853725B (zh) | 包含锌氨基酸卤化物的口腔护理组合物 | |
| CN104853724B (zh) | 锌氨基酸卤化物漱口剂 | |
| RU2634261C2 (ru) | Комплекс цинк-аминокислота-галогенид с цистеином | |
| EP3386466A1 (en) | Metal amino acid complexes for bacterial aggregation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |